InnovationsKapital: Latest News

companyNews - 14 Maj, 2012 - Isconova: Framgångsrik fas I-studie med Isconovas Matrix M™-adjuvans

2012-05-14 16:17:38

I studien vaccinerades en grupp äldre patienter (i åldrarna 65-75) med antingen Vaxigrip® (spjälkat inaktiverat vaccin mot säsongsinfluensa) adjuvanterat med Matrix M™ eller med endast Vaxigrip®. Det adjuvanterade vaccinet var vältolererat med en utmärkt säkerhetsprofil. En ökning av smärre biverkningar jämfört med det icke-adjuvanterade vaccinet observerades, men dessa var milda och övergående. Inga allvarliga biverkningar noterades. Både det adjuvanterade och icke-adjuvanterade vaccinet uppfyllde alla tre EMA-serologiska bedömningskriterier för regulatoriskt godkända säsongsinfluensavaccin. Ett starkare antikroppssvar noterades i den Matrix M™-adjuvanterade gruppen. Interferon gamma-producerande CD4-celler återfanns i signifikant högre nivåer i Matrix M™-gruppen vid dag 28 och dag 90 efter vaccination och var fortfarande förhöjt dag 150. Dessa celler anses vara en viktig markör för potent immunsvar. Studien bekräftar den kliniska överlägsenhet som redan påvisats i den studie av Matrix M ™ för pandemiskt influensavaccin som genomfördes av J&J/Crucell (PanFluVac), inklusive den viktiga ökningen av det cellmedierade immunsvaret. Professor Ab Osterhaus, världsledande influensaexpert och Chief Scientific Officer ViroClinics Biosciences BV, Rotterdam, kommenterade; "Matrix M™ presterade anmärkningsvärt väl i denna humanstudie. Adjuvansen stimulerade både antikroppssvar och cellulära svar med en mycket god säkerhetsprofil." Sven Andréasson, VD Isconova AB, kommenterade; "Det här är en viktig framgång för oss och ytterligare ett bevis på att Isconovas egenutvecklade Matrix M™-plattform har potentialen att förbättra vaccin för människor på en växande marknad med ett stort medicinskt behov. Dessa data är avgörande för att etablera ”proof of concept” för den vidare kommersialiseringen av Matrix M™." För mer information, vänligen kontakta: Sven Andréasson, VD, Isconova AB Tel: 46 701 60 60 60 E-post:sven.andreasson@isconova.com

companyNews - 14 Maj, 2012 - Isconova: Successful Phase I Study Using Isconova’s Matrix MTM Adjuvant

2012-05-14 14:48:26

In this trial, a group of elderly subjects (aged 65-75) were administered either Vaxigrip® (seasonal influenza split vaccine) adjuvanted with Matrix MTM or Vaxigrip® alone. The adjuvanted vaccine was well tolerated with an excellent safety profile. An increased number of minor side-effects compared to the non-adjuvanted comparator vaccine were observed, however these were mild and transient. No severe side-effects were recorded. Both the adjuvanted and non-adjuvanted vaccines fulfilled all three EMA serological assessment criteria for regulatory approval of seasonal influenza vaccines. Higher antibody responses were seen in the Matrix MTM adjuvanted group. Interferon gamma producing CD4 cells were found at significantly higher levels in the Matrix M™ group on days 28 and 90 and were still elevated on day 150. These cells are considered to be an important marker of a potent immune response. The study confirms the clinical superiority of the Matrix M™ adjuvanted vaccine, already demonstrated by the use of Matrix MTM in the previously conducted pandemic influenza vaccine study in man (PanFluVac), by Isconova’s partner J&J / Crucell, including the important increase in the cell mediated immune response. Professor Ab Osterhaus, world leading influenza expert and Chief Scientific Officer of ViroClinics Biosciences BV, Rotterdam, commented; “The adjuvant Matrix MTM performed remarkably well in this human trial. It stimulated both antibody and cellular responses with an excellent safety profile.” Sven Andréasson, Chief Executive Officer of Isconova AB, Uppsala, commented; “This is an important achievement for us and is further evidence that Isconova’s proprietary Matrix M™ platform has the potential to improve vaccines for humans in a growing market where there remain major unmet needs. The data are crucial for the proof of concept for our further commercialization of Matrix M™.” For more information, please contact: Sven Andréasson, Chief Executive Officer of Isconova AB Tel: +46 701 60 60 60 E-mail: sven.andreasson@isconova.com NOTES TO EDITORS About Isconova Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden. Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser. www.isconova.com About the influenza study • Vaxigrip® (seasonal influenza split vaccine) adjuvanted with Matrix MTM was tested and compared with Vaxigrip® alone in two groups (n= 44 per group) of elderly subjects , aged 65-75. • The specific T-cell mediated response was significantly higher in the group receiving the Matrix MTM adjuvanted vaccine. This was measured with respect to the percentage of influenza virus reactive CD4+ cells producing: o Interferon gamma at day 28 and 90 (P<0.05). • Both the adjuvanted and non-adjuvanted vaccines induced high levels of antibodies and both groups conform to all three EMA serological assessment criteria for regulatory approval of seasonal influenza vaccines; o The Hemagglutination Inhibition (HI) Seroconversion Rate; was higher against all three strains in the Matrix MTM adjuvanted vaccine. Even at day 150, seroconversion rates were 8% or higher among elderly receiving the Matrix MTM adjuvanted vaccine. o The Geometric Mean Titer (GMT) increase of HI; was higher for all three strains in the Matrix MTM adjuvanted vaccine at day 28 and 150. o The Seroprotection Rate by HI; was equal or higher for all three strains in the Matrix MTM adjuvanted vaccine at day 28 and 150. • The GMT increase of Virus Neutralization Antibodies (VNA) was significantly higher for the homologous H1N1 strain in the Matrix MTM adjuvanted vaccine group at day 28 and 90. In addition, the GMT increase of VNA was higher for the homologous B strain in the Matrix MTM adjuvanted vaccine group at day 28 and 150. • The Matrix MTM adjuvanted vaccine was well tolerated. An expected increase of minor side-effects compared to the non-adjuvanted comparator vaccine was observed. The reactogenicity was mild and transient. No severe side effects were recorded. • The results of this phase I study in elderly subjects demonstrate that Matrix MTM is well tolerated and significantly stimulates the T-cell response. Furthermore, the results indicate an increase of the serological response and duration. • The study forms a part of the clinical proof of concept for the further development of Matrix MTM adjuvanted seasonal influenza vaccines with the potential for an increased clinical efficacy in the elderly population.

companyNews - 10 Maj, 2012 - Oxeon: Case Study on Volvo Polestar Racing's TeXtreme® usage

2012-05-11 14:24:02

The case study has been published on two magazines websites: Professional Motorsport World and Race Tech Magazine. To read the two articles please follow the links below: Professional Motorsport World - Case Study: Polestar's composite parts Race Tech Magazine – Tip Tows A pdf version of the Race Tech Magazine is available in the Technical Literature section.

companyNews - 27 April, 2012 - Congratualtions to Red Herring's 2012 top 100 European award winners - Abionic SA, AlphaSIP, BONESUPPORT AB, Morflora, NovImmune SA, StereoTools SA, CERENIS THERAPEUTICS, Miracor Medical Systems, Modz Ltd, Relaxbirth Ltd.

2012-05-04 17:23:41

This exceptional group of companies are among the most innovative, unique and promising companies selected from a pool of hundreds from across Europe. The Top 100 were evaluated on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, IP creation, CAGR, execution of strategy, and disruption in their respective industries Abionic SA, Switzerland AlphaSIP, Spain BONESUPPORT AB, Sweden Morflora, Israel NovImmune SA, Switzerland StereoTools SA, Switzerland CERENIS THERAPEUTICS, France Miracor Medical Systems, Austria Modz Ltd Life, Finland Relaxbirth Ltd., Finland Congratuations from all at BioPortfolio.com!

innkapNews - 3 Maj, 2012 - Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

2012-05-04 15:24:16

AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in adjacent indications. AP214 is a hormone analogue that targets both systemic inflammation and cellular death (apoptosis) caused by hypoxia (lack of blood flow) that can occur during surgery. In September 2011, Action Pharma announced positive Phase 2b top-line results evaluating the efficacy, safety and tolerability of AP214. Abbott plans to conduct another Phase 2b study, which is expected to begin later this year. This acquisition will enhance Abbott's pipeline in renal care. Abbott has two investigational treatments in development for chronic kidney disease (CKD). Bardoxolone, a first-in-class antioxidant inflammation modulator that activates Nrf2, a pathway involved in the progression of CKD, is in Phase 3 development with Reata Pharmaceuticals. Atrasentan, a compound discovered by Abbott scientists, is being evaluated in a Phase 2b study in patients with diabetic kidney disease. "Clinical experience with AP214 in cardiac surgery patients suggests that it has the potential to be the first compound specifically approved to prevent acute kidney injury, a long-standing unmet need in the medical community," said John Leonard, M.D., senior vice president, pharmaceuticals, research and development, Abbott. "This acquisition complements and broadens Abbott's late-stage renal care pipeline and builds on our existing experience in treating kidney disease." "We are very excited about the sale of AP214 to such a prominent global health care company as Abbott, which has key development competencies to continue the development of this drug candidate for the benefit of patients and physicians in the renal therapeutic area," said Ingelise Saunders, CEO of Action Pharma. "We also wish to thank our shareholders for their continued support of Action Pharma." Under the terms of the agreement, Abbott will acquire all global rights to develop and commercialize AP214 for the prevention of AKI and other relevant indications. Abbott will provide a cash payment of $110 million to Action Pharma and will be responsible for funding all future development and commercialization activities regarding AP214. No later milestone payments or royalties will be paid to Action Pharma. Abbott expects to incur a one-time specified item in the second quarter of 2012, related to this payment. In 2003, Action Pharma in-licensed Zealand Pharma A/S' (NASDAQ OMX Copenhagen: ZEAL) SIP® technology for use with pro-opiomelanocortin derivatives. As part of the agreement between Abbott and Action Pharma, Action Pharma's original licensing agreement with Zealand Pharma regarding the SIP® technology is cancelled, and superseded with a new agreement between Abbott and Zealand Pharma (see separate announcement from Zealand Pharma) regarding the SIP® technology. Upon the closing of the Abbott and Action Pharma transaction, Action Pharma will make a one-time payment to Zealand Pharma of $11 million. Zealand Pharma will also be entitled to a low single-digit royalty on Abbott's future global sales of AP214 (referred to as ZP1480 by Zealand Pharma). Since 2003, Action Pharma has solely developed AP214 to its current clinical status. Back Bay Life Science Advisors provided strategic advisory services for Action Pharma prior to and throughout the transaction. Contact information Action Pharma Ingelise Saunders, CEO E-mail: ils@actionpharma.com Phone: +45 2020 3687 Abbott Media: Financial: Scott Stoffel Larry Peepo Phone: +1 847 936 9502 Phone: +1 847 935 6722 Liz Shea Phone: +1 847 935 2211 About Acute Kidney Injury Associated with Major Cardiac Surgery Acute kidney injury (AKI) is known to be associated with increased short- and long-term mortality and co-morbidity, as well as prolonged hospitalization and permanent decline in renal function. Currently there are no pharmaceuticals on the market for the treatment or prevention of AKI associated with major cardiac surgery. About Action Pharma A/S Action Pharma is a privately-owned Danish biotech company. Action Pharma has for almost ten years focused on developing novel drug candidates targeting melanocortin receptors and bring these to the stage of clinical proof of concept for subsequent partnering. Action Pharma has a strong investor base of leading European investors, including Sunstone Capital, Global Life Science Ventures, SLS Invest, InnovationsKapital, Incuba Venture, and Oestjysk Innovation. For more information, please visit www.actionpharma.com About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries. Abbott’s news releases and other information are available on the company's website at www.abbott.com Abbott Forward Looking Statement Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements: Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2011, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

companyNews - 3 Maj, 2012 - Action Pharma: Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury

2012-05-04 13:54:19

AP214 is in development to prevent acute kidney injury (AKI) associated with major cardiac surgery in patients at increased risk and has further potential in adjacent indications. AP214 is a hormone analogue that targets both systemic inflammation and cellular death (apoptosis) caused by hypoxia (lack of blood flow) that can occur during surgery. In September 2011, Action Pharma announced positive Phase 2b top-line results evaluating the efficacy, safety and tolerability of AP214. Abbott plans to conduct another Phase 2b study, which is expected to begin later this year. This acquisition will enhance Abbott's pipeline in renal care. Abbott has two investigational treatments in development for chronic kidney disease (CKD). Bardoxolone, a first-in-class antioxidant inflammation modulator that activates Nrf2, a pathway involved in the progression of CKD, is in Phase 3 development with Reata Pharmaceuticals. Atrasentan, a compound discovered by Abbott scientists, is being evaluated in a Phase 2b study in patients with diabetic kidney disease. "Clinical experience with AP214 in cardiac surgery patients suggests that it has the potential to be the first compound specifically approved to prevent acute kidney injury, a long-standing unmet need in the medical community," said John Leonard, M.D., senior vice president, pharmaceuticals, research and development, Abbott. "This acquisition complements and broadens Abbott's late-stage renal care pipeline and builds on our existing experience in treating kidney disease." "We are very excited about the sale of AP214 to such a prominent global health care company as Abbott, which has key development competencies to continue the development of this drug candidate for the benefit of patients and physicians in the renal therapeutic area," said Ingelise Saunders, CEO of Action Pharma. "We also wish to thank our shareholders for their continued support of Action Pharma." Under the terms of the agreement, Abbott will acquire all global rights to develop and commercialize AP214 for the prevention of AKI and other relevant indications. Abbott will provide a cash payment of $110 million to Action Pharma and will be responsible for funding all future development and commercialization activities regarding AP214. No later milestone payments or royalties will be paid to Action Pharma. Abbott expects to incur a one-time specified item in the second quarter of 2012, related to this payment. In 2003, Action Pharma in-licensed Zealand Pharma A/S' (NASDAQ OMX Copenhagen: ZEAL) SIP® technology for use with pro-opiomelanocortin derivatives. As part of the agreement between Abbott and Action Pharma, Action Pharma's original licensing agreement with Zealand Pharma regarding the SIP® technology is cancelled, and superseded with a new agreement between Abbott and Zealand Pharma (see separate announcement from Zealand Pharma) regarding the SIP® technology. Upon the closing of the Abbott and Action Pharma transaction, Action Pharma will make a one-time payment to Zealand Pharma of $11 million. Zealand Pharma will also be entitled to a low single-digit royalty on Abbott's future global sales of AP214 (referred to as ZP1480 by Zealand Pharma). Since 2003, Action Pharma has solely developed AP214 to its current clinical status. Back Bay Life Science Advisors provided strategic advisory services for Action Pharma prior to and throughout the transaction. Contact information Action Pharma Ingelise Saunders, CEO E-mail: ils@actionpharma.com Phone: +45 2020 3687 Abbott Media: Financial: Scott Stoffel Larry Peepo Phone: +1 847 936 9502 Phone: +1 847 935 6722 Liz Shea Phone: +1 847 935 2211 About Acute Kidney Injury Associated with Major Cardiac Surgery Acute kidney injury (AKI) is known to be associated with increased short- and long-term mortality and co-morbidity, as well as prolonged hospitalization and permanent decline in renal function. Currently there are no pharmaceuticals on the market for the treatment or prevention of AKI associated with major cardiac surgery. About Action Pharma A/S Action Pharma is a privately-owned Danish biotech company. Action Pharma has for almost ten years focused on developing novel drug candidates targeting melanocortin receptors and bring these to the stage of clinical proof of concept for subsequent partnering. Action Pharma has a strong investor base of leading European investors, including Sunstone Capital, Global Life Science Ventures, SLS Invest, InnovationsKapital, Incuba Venture, and Oestjysk Innovation. For more information, please visit www.actionpharma.com About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries. Abbott’s news releases and other information are available on the company's website at www.actionpharma.com Abbott Forward Looking Statement Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements: Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2011, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

companyNews - 19 April, 2012 - Santaris Pharma A/S: Santaris Pharma A/S presents final Phase 2a study results for miravirsen showing dose-dependent, prolonged antiviral activity in Hepatitis C patients

2012-04-25 14:22:51

-- Data to be presented in oral presentation at EASL Annual Meeting - - Miravirsen is a host-targeted, pan-HCV genotype anti-viral agent and the first microRNA-targeted drug to enter clinical trials - Miravirsen was safe, well tolerated and provided prolonged antiviral activity, with no signs of viral resistance - Miravirsen provided robust, dose-dependent antiviral activity with a mean reduction of 2 to 3 logs from baseline in hepatitis C virus (HCV) RNA (log10 IU/mL) that was sustained well beyond (> 4 weeks) the end of therapy - Four out of nine patients treated at the highest dose with miravirsen became HCV RNA undetectable during the study, providing clinical evidence that miravirsen's unique mechanism-of-action offers the potential for treatment cures when used as monotherapy - Miravirsen's long-lasting suppression of HCV RNA, high barrier to viral resistance, low propensity for drug interactions and favorable tolerability and dosing profiles holds promise as new treatment option given as monotherapy or in combination with direct acting antiviral agents HOERSHOLM, Denmark and SAN DIEGO, April 19, 2012 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy. These final clinical data are being presented at the International Liver Congress™ 2012, the annual meeting of the European Association for the Study of the Liver (EASL), taking place on April 18 – 22 in Barcelona, Spain. (Logo:http://photos.prnewswire.com/prnh/20100111/SPLOGO Clinical data from the Phase 2a study will be presented in an oral presentation on April 20, 2012 at 5:15 p.m. CEST, titled "Final Results: Randomized, Double-Blind, Placebo-Controlled Safety, Anti-Viral Proof-of-Concept Study of Miravirsen, an Oligonucleotide Targeting miR-122, in Treatment-Naive Patients with Genotype 1 Chronic HCV Infection." Study results demonstrated the following: •Miravirsen was safe and well tolerated •Adverse events were generally infrequent, mild and similar between treatment groups •No dose limiting toxicities or any discontinuations due to adverse events •Miravirsen was associated with dose-dependent reductions in HCV RNA that were sustained well beyond the end of the four-week dosing period •Four out of nine patients treated at the highest dose (7 mg/kg) with miravirsen became HCV RNA undetectable with just five weekly doses of miravirsen monotherapy •No evidence of viral resistance "These data provide clinical evidence that miravirsen's unique mechanism-of-action offers a high barrier to viral resistance and the potential for cure with monotherapy. Due to its ability in targeting miR-122, miravirsen has the potential to change the way hepatitis C is treated," said Dr. Henk Reesink, Academic Medical Center, University of Amsterdam, who is presenting the data at EASL. "These data show that longer duration of miravirsen monotherapy has the potential to produce sustained virological responses." The mean of the maximum decline from baseline in HCV RNA (log10 IU/mL) over the 18 week study was 1.2, 2.9, 3.0 in the 3, 5 and 7 mg/kg miravirsen dose groups respectively vs. 0.4 in the placebo group (Table 1). Table 1: Mean of the Maximum HCV RNA (Log10 IU/mL) Change from Baseline in all 3 Cohorts Dose Group Mean Maximum HCV RNA decline IU/mL (SEM) p-value (t) MIR vs. placebo Pooled placebo 0.4 (0.4) --- Miravirsen 3 mg/kg 1.2 (0.6) 0.011 Miravirsen 5 mg/kg 2.9 (1.7) 0.003 Miravirsen 7 mg/kg 3.0 (1.6) 0.002 "We are pleased that the final data set reinforces that miravirsen, the first microRNA-targeted drug to be given to patients, provides long-lasting suppression of HCV RNA, has a high barrier to viral resistance and favorable tolerability and dosing profiles," said Michael R. Hodges, MD, Vice President and Chief Medical Officer at Santaris Pharma A/S. "Miravirsen has the potential to be used in combination with direct acting anti-viral agents as part of an interferon-free, dosing regimen in patients with all types of HCV genotypes." The randomized, double-blind, placebo-controlled, ascending multiple-dose Phase 2a study assessed the safety and tolerability of miravirsen in treatment-naïve patients with chronic HCV genotype 1 infection. Patients with chronic HCV genotype 1 infection were enrolled sequentially to one of three cohorts (9 active: 3 placebo per cohort) at doses of 3, 5 and 7 mg/kg. Miravirsen was given as a total of 5 weekly subcutaneous injections over 29 days. Additional data supporting the final results in the miravirsen Phase 2a study will also be presented in posters demonstrating evidence of its high barrier to resistance and favorable dosing schedule: •"Preclinical characterization of miravirsen (miR), an oligonucleotide targeting miR-122 in the HCV genotype 1B Replicon System" – Soren Ottosen, et al.; April 20, 2012 from 12:30-2 p.m. CEST •"Pharmacokinetics of miravirsen, a miR-122 inhibitor, predict the prolonged viral load reduction in treatment naïve genotype 1 HCV infected patients" – Robert Persson, et al.; April 21, 2012 from 12:30-1:30 p.m. CEST •"Sequence analysis of HCV variants from a Phase IIa trial of miravirsen (miR), an oligonucleotide targeting miR-122, in treatment naive patients with chronic HCV infection" – A.K. Patick, et al.; April 21, 2012 from 12:30-1:30 p.m. CEST Developed using Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform, miravirsen is an inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication. Miravirsen is designed to recognize and sequester miR-122, making it unavailable to the Hepatitis C virus. As a result, the replication of the virus is effectively inhibited and the level of Hepatitis C virus is profoundly reduced. About Hepatitis C Hepatitis C infection is a viral disease caused by the Hepatitis C virus that leads to inflammation of the liver. The World Health Organization estimates about 3% of the world's population has been infected with HCV and that some 170 million have chronic hepatitis C and are at risk of developing liver cirrhosis and/or liver cancer[1]. Approximately 3-4 million Americans are chronically infected with an estimated 40,000 new infections per year[2]. In Europe, there are about 4 million carriers[1]. Treatment with pegylated interferon in combination with ribavirin is effective in only about 50% of those treated[2]. Patients that are not effectively treated have an increased risk for the progression of liver disease. By 2029, total annual medical costs in the United States for people with Hepatitis C are expected to more than double, from $30 billion in 2009 to approximately $85 billion[3]. About microRNAs MicroRNAs have emerged as an important class of small RNAs encoded in the genome. They act to control the expression of sets of genes and entire pathways and are thus thought of as master regulators of gene expression. Recent studies have demonstrated that microRNAs are associated with many disease processes. Because they are single molecular entities that dictate the expression of fundamental regulatory pathways, microRNAs represent potential drug targets for controlling many biologic and disease processes. About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against RNA targets, both mRNA and microRNA, for a range of diseases including cardiometabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders. LNA-based drugs are a promising new class of therapeutics that are enabling scientists to develop drug candidates to work through previously inaccessible clinical pathways. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies to deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The unique combination of small size and very high affinity allows this new class of drugs candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles. The most important features of LNA-based drugs include excellent specificity providing optimal targeting; increased affinity to targets providing improved potency; and favorable pharmacokinetic and tissue-penetrating properties that allow systemic delivery of these drugs without complex and potentially troublesome delivery vehicles. About Santaris Pharma A/S Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company's research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire plc, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that comprise LNA as active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States. Please visit www.santaris.com for more information. Santaris Pharma A/S® is a registered trademark of Santaris Pharma A/S. SantarisTM and LNA-antimiR™ are trademarks of Santaris Pharma A/S. [1] World Health Organization http://www.who.int/csr/disease/hepatitis/Hepc.pdf [2] American Association for the Study of Liver Diseases - http://www.aasld.org/patients/Pages/LiverFastFactsHepC.aspx [3] Institute of Medicine of the National Academies. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Colvin HM and Mitchell AE, ed. Available at: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.iom.edu%2FReports%2F2010%2FHepatitis-and-Liver-Cancer-A-National-Strategy-for-Prevention-and-Control-of-Hepatitis-B-and-C.aspx&esheet=50004789&lan=en-US&anchor=http%3A%2F%2Fwww.iom.edu%2FRepo

companyNews - 3 April, 2012 - Projectplace: Projectplace Receives Security ISO Certification

2012-04-19 14:25:33

ISO27001 is the international standard that certifies a high level of information security, including proactive management as well as the evaluation and addressing of risks. SaaS companies and cloud technologies have been scrutinized since the first startups in these fields emerged. The clients entrust important business data to a third party, and because of this information security is a top priority for Projectplace. ”The way we handle information is very important to our clients”, said Walter Werner, Chief Information Security Officer at Projectplace. “When we talk to new clients, the subject of information security is always one of the first questions to come up. Most of the concerns are covered by this certificate.” Intertek Certification AB, who led the ISO 27001 evaluation process, was very impressed by Projectplace. “Projectplace’s employees are very committed and responsible, which is key when it comes to security related issues,” said Per Ove Olausson, Lead Auditor at Intertek Certification AB. ”Everyone demonstrated a great deal of dedication and passion, which also shows in the quality of service Projectplace offers.” The ISO 27001 certification focuses on the management as well as on structural and technical aspects of information security. The rigorous control of source code at Projectplace did not pass by unnoticed during the audit. “On the technical level of this security evaluation we found that Projectplace is remarkably good at securing their code. It is actually the highest quality I have encountered.” said Per Ove Olausson. Securing client data is a top priority for Projectplace. With the ISO 27001 the company has received a significant third party verification that vouches for the secure structures within the organization. The certification is a proof of what existing clients have benefited from for over a decade. International Media Contact: Niklas Rosvall, VP Marketing Phone: +4673 240 20 00, Email: niklas.rosvall@projectplace.com Press room for media: http://www.mynewsdesk.com/uk/pressroom/projectplace_international

companyNews - 12 April, 2012 - Apptus: Nordens ledande e-handelskoncern CDON fortsätter förstärka sökoptimeringen med Apptus Technologies

2012-04-13 14:12:00

Svenska Apptus Technologies har utvecklat en teknik för e-handlare som på ett ögonblick kartlägger konsumentens köp- och navigeringsmönster i realtid. Den självlärande algoritmen tolkar besökarens behov och föreslår produkter som passar, innan besökaren själv kommit på att fråga. Köpprocessen effektiviseras och besökarens sökbeteende registreras till nästkommande besök på siten. Över en halv miljon unika besökare assisteras varje dag av Apptus eSales sök, navigerings- och rekommendationsfunktioner. Redan vid samarbetets början 2001 märkte CDON Group en markant ökning i orderingång och försäljning tack vare eSales smarta funktioner. ”Apptus har den starkaste teknologin på marknaden där eSales smarta funktioner passar våra behov inom sökteknologi och artikelhantering”, säger Christofer Gordon, Chief Technological Officer på CDON Group. ”Vi tror starkt på att dynamiskt kartlägga besökarens sökbeteende istället för att segmentera besökarna i förutbestämda kategorier. Genom att eSales självlärande algoritm fångar upp sökmönster hos varje enskild besökare kan vi vara mycket mer träffsäkra i fråga om relevans för besökaren.” CDON Group har en tydlig ambition att ligga i framkant inom användningen av den teknologiska utvecklingen. Visionen är att fortsätta vara den ledande aktören inom samtliga e-handelssegment i Norden och på sikt etablera bolaget som en ledande aktör på den europeiska marknaden. Ramavtalet med Apptus gäller siterna CDON, Bookplus, Gymgrossisten, Bodystore, Fitnesstukku, Nelly, LinusLotta, Heppo, Lekmer, Tretti och Rum21. ”Apptus eSales analyserar kundernas köpmönster och beteende i realtid i syfte att ge varje enskild besökare så relevanta svar och rekommendationer som möjligt” säger Michael Mokhberi, VD på Apptus. Tina Jensen, Marketing Communications, Apptus Technologies AB Telefon: 46 701 66 41 07, e-post: tina.jensen@apptus.com Om Apptus Technologies Apptus Technologies tillhandahåller en världsledande, blixtsnabb motor för e-handel och sök. Den självlärande tekniken ger direkt tillgång till relevant information. Apptus hjälper företag i över fyrtio länder att göra bättre affärer. Bland kunderna finns Sensis, Eniro, Hitta, Bokus, Cdon och Nelly. Nyligen expanderade bolaget till England, men huvudkontoret ligger i Lund. Bolaget grundades 2000. Mer information om Apptus finns på www.apptus.com

companyNews - 30 March, 2012 - Paxport: Paxport AB names Peter Lövgren as new CEO

2012-03-30 16:16:05

Peter Lövgren has taken over as new CEO of Paxport AB, as part of a strategy to power the company's European expansion. Paxport is a Swedish company within the charter/ leisure airline industry providing solutions that enhances and makes the passenger's travel experience more seamless. This in turn creates more sales revenue as the passenger is demanding additional services. Peter Lövgren has extensive experience in the IT industry, including CEO of Sun Microsystems Sweden, Microsoft Sweden, and Song Networks AB. He also holds a number of board positions in technology-oriented growth companies, including the chair of Projectplace International, Elements AB and Proximion Fiber Systems AB. "Paxport is an exciting company with a product that provides real added value. I look forward to contributing with my experience and take the company to new heights in Europe," says Peter Lövgren. For further information please visit: www.paxport.se

companyNews - 27 March, 2012 - Paxport: Balkan Holidays in partnership with Paxport, launch a Travel Agent interface for its Summer 2012 in-flight ancillary products

2012-03-30 16:14:41

These products are now pre-bookable directly by Travel Agents once the initial flight or package holiday booking has been made online. These services include, choice of seating, extra leg room, front row seats, extra checked baggage allowance, carriage of Skis and Golf Clubs. This product will allow Travel Agents selling Balkan Holidays, flying with BH Air, to purchase ancillary flight products via an interactive webshop, accessed via the current dedicated Travel Agency website. Mr Macura, Managing Director, Balkan Holidays commented, "Our wish is to give our Customers the highest level of service and choice which extends to their in-flight experience. We have been co-operating successfully with Paxport for over two years and we are very pleased to extend this relationship further to help facilitate the enhancement of the in-flight experience" Rupert Diggins, Sales & Marketing Manager, added, "I am delighted that our travel agent partners can now take advantage of this simple to use online service and enhance their clients flight and holiday experience still further". Carl Denton, Sales Manager, UK & Ireland commented "Paxport is very happy to extend its relationship with Balkan Holidays and to extend its existing services to its Travel Agent Partners who we know are very important part of Balkan Holiday's success" Balkan Holidays is an independent specialist Tour Operator with 46 years of experience in planning and arranging memorable holidays and offers the most comprehensive choice and best possible value for money holidays for holidays to Bulgaria, Croatia, Montenegro, Slovenia, Serbia and Romania. Paxport is Europe's leading ancillary revenue supplier for the charter airline industry and offers its airline and tour operator customers the means to generate additional revenues by giving passengers the opportunity to buy choice of seating, extra baggage, meals and other products before the flight and a solution for collecting security APIS data - all services have the added feature of giving airlines and tour operators a new touch point to offer sales of products and services to the passenger. For further information please visit: www.paxport.se

companyNews - 9 mars, 2012 - Projectplace; Projectplace Androidrustar

2012-03-20 16:20:16

– Vi satsar rejält nu inom social business. Vi ser att för den typ av tjänst som vi levererar blir mobilitet allt viktigare och för oss är det extremt viktigt att bredda erbjudandet, säger vd Johan Zetterström. Det innebär bland annat att bolaget vuxit ordentligt på personalsidan, men trots det är dte en bra bit kvar innan Johan Zetterström och Projectplace är nöjda. – Vi har ökat våra utvecklingsresurser rejält, från fyra till tolv personer, men vi hinner inte anställa i den takt vi vill. Under en övergångsperiod har vi tvingats jobba med ett antal externa konsulter, säger han och anger slutmålet: – Vi har två utvecklarteam idag, ett i Stockholm och ett i Bangalore. Generellt sett behöver vi dubblera antalet, totalt behöver vi vara drygt 60 utvecklare. När det gäller satsningen på mobilitetet så kommer allt mer krut att läggas på Androidutveckling. – Det har varit mycket IOS tidigare och det är fortfarande mycket brus kring det. Men vi har även många kunder som inte använder den plattformen av olika skäl. Vi har beslutat att vi lägger lika mycket resurser på Android som vi lägger på Ios, så att det blir två jämnstora team. Det blir dessutom en bra internkonkurrens mellan teamen, säger Johan Zetterström, som dock är noga med att poängtera att man hela tiden följer utvecklingen. – Vi har inte valt att bara stödja en viss plattform. Om Windows Mobile tar fart ordentligt behöver vi stödja den också. www.projectplace.se

companyNews - 13 mars, 2012 - Emric: Emric köper Extenda Financial Solutions Bolagsköp tar Emric närmare målet att bli marknadens självklara partner inom kreditgivning

2012-03-13 18:07:47

– Med förvärvet av Extenda Financial Solutions tar vi ett stort steg mot vårt långsiktiga mål – att med en integrerad standardlösning vara en fullvärdig partner för banker och kreditinstitut i hela världen. Vi har lagt en roadmap för vilket erbjudande vi vill ha och nu blir vi än starkare inom vissa delar avseende kreditadministration och inlåning. Tack vare bolagsköpet kan vi nu även erbjuda en modern front-backlösning för bolån och företagskrediter, säger Emrics VD Joakim Dahlgren. Företagsköpet är också en del i Emrics tillväxtstrategi. Om några år avser Emric att, genom organisk tillväxt och ytterligare förvärv, ha nått en omsättning på minst en halv miljard kronor. – Med Extenda Financial Solutions får vi in ytterligare 33 duktiga medarbetare med hög kompetens inom bank och finans, vilket ökar antalet medarbetare på Emric från 170 till närmare 200, säger Joakim Dahlgren. Emric, som i Sverige har kunder som SEB, SBAB, Handelsbanken, Danske Bank och Länsförsäkringar Bank, har sedan starten 1994 haft en stadig och lönsam tillväxt. De senaste åren har tillväxten accelererat, för drygt ett år sedan förvärvade Emric bolaget Financial Systems FS AB och hösten 2011 öppnades ett Indonesien-kontor som vid årets slut kommer att ha ca 20 medarbetare. Förutom huvudkontoret i Stockholm och off shore-verksamheten för utveckling i Indonesien har bolaget en fullskalig outsourcingverksamhet i Kalix samt kontor i Uppsala, Storbritannien och Serbien. Emric erbjuder marknaden kraftfulla systemstöd som optimerar och effektiviserar kreditprocessen. Systemen finns idag installerade i ett tjugotal länder runt om i världen. Utöver detta erbjuder Emric verksamhets- och IT konsulttjänster samt tjänsten Finance Process Outsourcing; ”nyckelfärdiga finansbolag” vilket innebär att Emric kan ta uppdraget att sätta upp en helt ny kreditverksamhet samt ta hand om den operativa verksamheten. Emric kan även ta över en befintlig kreditadministration och därmed erbjuda kunden en mer kostnadseffektiv lösning. – För oss på Extenda Financial Solutions är förvärvet ett sätt att ta ett steg till nästa nivå. Nu kan vi ta våra backoffice-produkter vidare mot nya kunder och marknader, även internationellt. Som en del av Emric blir vi en marknadsledande leverantör av lösningar för kreditgivning, vilket ger oss betydligt större möjligheter att få ut våra produkter och lösningar, säger Juha Duvaldt, vd för Extenda Financial Solutions. – Många banker sitter med flera olika egenutvecklade system för att hantera sin affär och har byggt upp en omfattande IT-infrastruktur som de lägger ner stora pengar på att vidareutveckla och underhålla själva, kostnader som i slutändan belastar slutkunden. Vår ambition är att erbjuda dem en integrerad standardlösning samt vid behov även outsourcing som gör att de kan sänka sina kostnader avsevärt, avslutar Joakim Dahlgren. För mer information, vänligen kontakta: Joakim Dahlgren, VD, Emric Tel: 08-400 28 400, mobil: 070-979 03 05 e-post: joakim.dahlgren@emric.com Extenda Financial Solutions erbjuder bank- och finansbranschen system för kreditgivning, finansiering och inlåning. Kunderna finns huvudsakligen i Sverige och Finland, dessutom används systemen i Norge och Baltikum. Omsättningen uppgick till 33 miljoner kronor år 2011 och Extenda Financial Solutions var tidigare en del av Extendagruppen som år 2011 omsatte drygt 200 miljoner kronor med cirka 170 anställda. Emric är en heltäckande partner inom kreditgivning för banker, finansbolag och kreditinstitut. Bolaget avknoppades från bank- och finansvärlden 1994 och sedan dess har verksamheten alltmer renodlats till att idag helt fokusera på att erbjuda verksamhetskunnande, outsourcing och kraftfulla systemstöd för de olika stegen i kreditprocessen. Emric har i dag ett komplett erbjudande för alla delar inom en kreditprocess för banker och kreditgivare över hela världen som vill effektivisera sina kreditprocesser. Efter förvärvet av Extenda Financial Solutions har Emric cirka 200 medarbetare inom de tre affärsområdena Software Solutions, Outsourcing och Consulting. Omsättningen beräknas uppgå till 220 miljoner kronor, varav ungefär en tredjedel genereras i andra länder än Sverige. Utöver huvudkontoret i Stockholm finns lokala kontor i Kalix, Uppsala, London, Belgrad och Jakarta. Läs mer på www.emric.com

companyNews - 1 March, 2012 - Medius: IBS Enters into Strategic Partnership with Medius AB to Offer Workflow and Automation Solution

2012-03-02 12:48:11

“Medius is known for its world-class workflow solutions with Mediusflow™, its complete workflow platform, and this partnership provides IBS customers with the ability to optimize, automate and reduce business process costs, as well as improve efficiencies throughout IBS Enterprise,” said Christian Paulsson, acting chief executive officer and chief operating officer. “Medius customers can also take advantage of IBS’ Distribution Cloud Solutions for lower IT cost, reduced business risk, faster time to value and greater flexibility. “ The strategic partnership is comprised of three major components, which includes a jointly developed interface between Mediusflow™ and IBS Enterprise, to ensure seamless workflow processes for key business processes; replacing IBS A/P Workflow™ with Medius’ robust procure-to-pay workflow solution; and providing IBS customers with a workflow tool to support different modes of delivery, including web, email and mobile devices. IBS will continue to support current installations of IBS A/P Workflow through 2015. The Mediusflow product will be part of IBS consulting services product portfolio and allows IBS customers to better manage approval processes to reduce costs, improve accuracy and strengthen internal controls. The IBS cloud offering is a subscription-based license model that leverages a shared, virtualized infrastructure for on-demand offerings and can also be extended to IBS’ mobility solution. “Customers interested in combining the power of one of the top ERP suppliers along with one of the most robust workflow and automation systems in the market should look no further than the product offered through this partnership,” said Per Nordling, chief executive officer, Medius. “Our combined technical effort and integration will surely help to build a stronger link between the transaction-based nature of an ERP system and the process-based character of a workflow solution.” Read more about IBS Worklow About IBS Stockholm-based International Business Systems (IBS) is a leading global integrated ERP and supply chain provider. Thousands of customers in over 40 countries rely on IBS for world-class solutions to drive dramatic improvements in their operations. IBS operates Dynaman, an advanced warehouse management solution and Bookmaster, a leader in ERP technology for publishing. For more information, contact www.ibs.net About Medius Medius was founded in Sweden in 2001 and provides leading business support that simplifies and streamlines business processes. Medius’ services and solutions are based on its proprietary workflow platform Mediusflow™. Mediusflow™ enables companies to quickly move from concept to solution in order to automate and optimize business processes that often are outside of the ERP system’s capacity. Currently, over 700 customers are enjoying the benefits of fully automated workflow solutions through Mediusflow™. Today Medius is established in a number of markets worldwide and maintains strong growth under controlled conditions and controlled profitability. For more information, contact www.medius-group.com

companyNews - 27 February, 2012 - Aepona: Aepona Announces Agile Service Enablement for its NaaS Solution

2012-02-28 16:12:13
Aepona’s Network as a Service Solution now comprises Agile Service Enablement, Telecom Web Services, Payments and Settlement Engine and Partner Management Engine. These components are integrated as the API Monetization Platform, which is an evolution of Aepona’s award-winning Universal Service Platform. The platform has been deployed by multiple Service Providers globally for their Network as a Service offerings, including Rogers, Neustar, Telus, Bell Canada, TDC and Sprint, as well as by the GSMA for its OneAPI Canadian commercial service. Aepona also announced today its selection by Belgacom for its BeOpen API service. The new Agile Service Enablement features allow service providers to quickly and easily create API services and mashups through configuration, rather than programming, meaning fast time to revenue and complete flexibility in service creation. New API services that combine core service provider assets, such as communications, network control, billing and context-awareness, with external APIs from web service providers, enterprises, content providers and merchants, can be rapidly composed and launched, and new functionality easily added as the service evolves. Agile Service Enablement can also be used in conjunction with legacy service delivery platforms to add functionality to pre-existing APIs, such as policy, authorization and charging for their use by partners. This provides investment protection for service providers that wish to evolve their API services without costly re-engineering of their legacy platforms, providing a future-proof, flexible environment for rapid service creation and monetization. Thanks to the close integration between Agile Service Enablement and Aepona’s Payments and Settlement Engine, another component of Aepona’s Network as a Service solution, services created within Agile Service Enablement can be monetized in multiple ways, according to the business relationship between the service provider and the partner, and the type of application consuming the service. Policies and charging rules can be applied on a per-partner and/or per-application basis, giving the service provider the flexibility to create innovative, attractive business models that are aligned with partners’ commercial models, allowing them to move away from the “one size fits all” approach of the past. “Agile Service Enablement allows Aepona’s Service Provider customers to better serve the needs of their partners, to differentiate their API services from their competitors, and to monetize their core assets in multiple ways,” said Richard McConnell, Aepona’s Chief Technology Officer. “An increasing number of service providers, such as mobile operators, multiple system operators, and cloud service providers, are opening up their core assets to external partners such as developers, enterprises and merchants, but are now looking beyond standard services such as messaging, location and payments. They want to offer more sophisticated API services that leverage their unique assets in new ways, and to combine these assets with external services to add even greater utility and value to partners. Agile Service Enablement gives them the flexibility and freedom to do this, gets them to market quickly, and most importantly, enables new revenue-generating solutions that drive their businesses forward”. In a separate release issued today, Aepona also announced its new Services Aggregation and Merchandizing platform, which allows service providers to aggregate, merchandize and deliver a range of cloud services, digital products and physical goods to customers. Together, Aepona’s API Monetization Platform and Services Aggregation and Merchandizing solutions allow service providers to add network value to cloud services in order to differentiate their offerings from competing service providers. For example, they can leverage network features made available by the API Monetization Platform, such as quality of service control, voice communications and contextual intelligence, to provide additional features and utility to the cloud services that they deliver through the Services Aggregation and Merchandizing platform. For further information please visit:

companyNews - 27 February, 2012 - Aepona: Aepona Announces New Services Aggregation & Merchandizing Platform

2012-02-28 13:52:26
The Service Aggregation And Merchandizing platform is already enabling communication service providers to generate over $300M in annual revenues. With this solution from Aepona, service providers will be able to aggregate and broker a broad range of cloud services, which, according to Gartner, will represent the single largest category in cloud computing by 2015. This will enable them to quickly launch new service bundles and targeted offers to produce new revenue streams with a cost efficient cloud based solution. SAM is a complete solution to manage the development and deployment of value-added services with full control and extensive partner integration. It enables service providers to generate additional revenue from new and existing subscribers, while reducing operational costs.´SAM provides the ability to customize product order and provisioning processes, manage the complexities of billing and invoicing and define settlement with service partners. With a comprehensive reporting facility and real time monitoring dashboards, SAM gives service providers the business intelligence to determine the optimal product and service mix, to select value add partners, to define effective channels and ultimately to develop compelling product and service bundles. Al Snyder, Aepona CEO, stated: “Service providers will be able to expand their position as the trusted provider of products and services by integrating third party products and services to their offer catalogue. This will significantly improve their customers’ experience and increase their revenue streams”. SAM supports the creation of partner ecosystems with the tools to successfully manage business partner relationships, onboard partners and define business models and settlement policies. With an extensive set of powerful APIs and interfaces, Aepona enables its customers to leverage all their existing system resources and integrate them with cloud based and Web based APIs to customize and expand their product and service offerings. Together with Aepona’s API Monetization Platform, AMP, network operators can add network value to cloud services to differentiate their offerings from competing service providers. For example, they can leverage network features such as quality of service control, voice communications and contextual intelligence to provide additional features and utility to the cloud services that they deliver. The Service Aggregation and Merchandizing platform is available now, and it is already a proven solution, deployed at a major North American operator. For further information please visit: www.aepona.com

companyNews - 27 February, 2012 - Oxeon: High-performance skis built with TeXtreme®

2012-02-28 13:48:00
ALT. Skis focuses on performance and every ski is handmade. Each ALT. ski design starts with the creation of a numeric model on which extensive finite-element analysis is conducted. This sophisticated design tool is the first stage to determine the ideal core profile as well as the optimal orientation of the carbon fiber in order to obtain the desired flexural and torsional rigidity. The carbon reinforcement surrounds the dual-density wood core to form a sandwich/sidewall race ski construction. In contrast to a cap ski construction, the sidewalls procure the ski edges a firm support for precision and high performance for any type of terrain and condition. "What is really great using TeXtreme® is that the fibers are holding their +-45 degree position really well during the wet layup process. Also, the binder being glue instead of stitching totally eliminates the imprint that we can get on the ski top sheet when we use stitch fabric as the top layer. The finish is very nice and smooth. And the look we are getting is by far the most appreciated of everything we tried", says Simon Bergeron, engineer and founder of ALT. Skis Inc. TeXtreme® Spread Tow Reinforcements are using spread tows to produce optimized reinforcements for ultra light composites. Spreading tows (yarns) into very thin tapes enables reinforcements in woven structure as well as unidirectional tapes with mechanical performance and possibility for weight savings that are unique compared to conventional reinforcements. About ALT. Skis Alt. Skis is performance. Inspired by aeronautic technologies, our high-end skis push established boundaries of durability, versatility and performance. ALT. skis are designed and handmade in Montreal, Canada. Internationally recognized for its aeronautic innovative engineering savoir-faire, the city offers Alt. Skis competitive advantage on research and development, on materials and on cutting-edge technologies. We’re also proud to benefit from one of the most progressive communities of freeskiers in the world. For further information please visit: www.oxeon.se

companyNews - 27 February, 2012 - Aepona: Belgacom Chooses Aepona for BeOpen API Initiative

2012-02-28 13:43:15
Belgacom’s BeOpen initiative will allow its partners to quickly and easily add network capabilities and intelligence to their applications, creating differentiation for consumer services and enabling productivity gains for business applications. The main goal of the BeOpen initiative is to create a vibrant ecosystem of application developers that will benefit Belgacom’s customers and partners through the creation of innovative new services. Commenting on Belgacom’s decision to select Aepona as the platform provider for BeOpen, Jan Paesen, Director Mobility at Belgacom said: “During the vendor evaluation process, Aepona clearly demonstrated their leadership in the market for OpenAPI platforms. As well as providing a best-in-class technical solution, the experience and knowledge of their team in the OpenAPI marketplace really shone through. We are confident that, as well as our platform provider, Aepona will prove to be a highly valuable business partner over the coming years.” Ingolf Ruh, Aepona’s SVP of Sales for EMEA and APAC, commented: “With the BeOpen project, Belgacom is fully embracing a new era of collaboration between Telcos and application partners, which will result in great benefits to consumers and businesses alike through more innovative services, better functionality and more convenient ways to pay. We are proud to have been chosen by Belgacom for this pioneering project and we are fully committed to partnering with them to ensure its long-term success.” For further information please visit: www.aepona.com

companyNews - 24 February, 2012 - Jasper: Mercury News interview: Kathryn Kranen, CEO of Jasper Design Automation

2012-02-28 13:20:39
By Steve Johnson Mercury Newsmercurynews.com It licenses "formal verification" software that helps chipmakers test their highly complex integrated-circuit designs to make sure they are free of bugs that might cause a personal computer, smartphone or other electronic device to malfunction. After weathering a rough period around 2005, Jasper's revenue has been growing 60 percent a year and the company - which has offices in Brazil, Sweden and Israel - is adding to its workforce of about 100 people, according to CEO Kathryn Kranen. In a recent interview, which has been edited for length and clarity, the 48-year-old Kranen talked about her company and her experiences as one of the Bay Area's rare women CEOs. Q: Jasper's business falls under a general category known as electronic design automation. What is that? A: I kind of fell in love with this industry in 1987 when I first joined it at one of the first EDA companies, Daisy Systems. What electronic design automation does is make tools -- mostly software, but some hardware as well -- that helps electrical engineers design all of the chips in every electronic device there is. It's a fundamental enabler for everything electronic. Q: Say a company designs a new chip for an automobile. How would your formal-verification software prevent the design from having a glitch that blows a car fuse, for example? A: What we do is all mathematical. We can just say there is a rule, or it's called a property, that this fuse should not blow. And then the software will automatically reverse engineer what conditions could cause that to fail. It tells you if you were driving in reverse while you moved your seat and shifted into park, the fuse will blow. It's very reliable. It solves problems about connections inside the chip. Q: Chipmakers are constantly updating their designs. How do you deal with that? A: You work with your customers and they work with all their vendors to make sure they have the capabilities they need to take on the next big design challenges. If you think about what's happened with the Internet and with smartphones -- especially with so much functionality in one device -- that is a huge design challenge. So it's been a big opportunity for our industry to step up and enable these things. Q: With your offices spread around the world, is it hard getting your employees to work well together? A: I learned in my last company, which was split between Israel and the United States, just how to get teams to work together in different geographies. When someone says, "They're idiots over there; they never know what they're doing," it just indicates they don't know the constraints, they haven't walked in their shoes. So I'm really good at saying, "Hmm, why don't you help him?" Then they come over and they say, "Oh, it turns out they're pretty smart after all." When you can put a team together and harness that diversity, it's great. Q: After serving as CEO of Verisity Design of Mountain View, which also offered design verification software, you were asked to become Jasper's CEO in 2003. Jasper ran into trouble before you finally turned things around. What happened? A: The founders left in late 2005, 2006. We call that the company's near-death experience, because our business went down. We weren't growing, we were shrinking and we lost all but one of our software developers here in Mountain View. It was taken down to bare metal. It was a big decision for me: "Do I want to stay and rebuild this?" I just believed so much in this technology. I knew this was going to be a leading company. Q: What's it been like as a woman moving up the career ladder in your industry? A: I've had investors say, "What are you thinking? How could you get pregnant while you're running a company?" I've had a European guy hitting on me and sending really crude mail. I remember one of my bosses. He was interviewing a woman for a very high-level sales type role and I asked, "What did you think of her?" And he said, "I don't know. It's hard for me to think of her meeting with a big CEO of a company." I thought, this is really stupid. And then I said, "The thing is, she's likely to get 60 more seconds with the CEO just out of courtesy. And that 60 more seconds might be exactly what's needed to make the key point to that person." I'm really happy with everybody I've ever worked with. But you are treated differently, in some good ways and some bad ways. Contact Steve Johnson at +1 408-920-5043 Kathryn Kranen Date of birth: Nov. 16, 1963 Place of birth: Dallas Residence: Menlo Park Position: President and CEO of Jasper Design Automation Education: Bachelor's degree in electrical engineering from Texas A&M University. Graduated summa cum laude. Previous jobs: President and CEO of Verisity Design; vice president of North American sales at Quickturn Systems; and design engineer at Daisy Systems and Rockwell International. Family: She and her husband, Kevin Kranen, have two children, Kyle, 13, and Kayla, 10. Five facts about Kathryn Kranen

She is deaf in her right ear, a condition her doctors believe was caused by chickenpox when she was an infant.

Her parents didn't tell her teachers about her deafness since they didn't want her "to think I was different," she said.

Her husband is director of strategic marketing at another electronic design automation company, Synopsys.

After moving to Silicon Valley in 1989, she fell in love with its inquisitive, innovative and diverse denizens, recalling "I felt like I found my people."

Her children like to brag that the chips she helps design are used in their favorite smartphones, gaming consoles and other electronic gadgets.
For further information please visit: www.jasper-da.com

companyNews - 20 February, 2012 - Cellartis: CELLARTIS TO BE PARTNER IN A MAJOR MULTINATIONAL IMI PROJECT SUPPORTED BY THE EUROPEAN COMMISSION AND THE EUROPEAN PHARMACEUTICAL INDUSTRY

2012-02-27 13:43:14
The current test systems employed by industry are poorly predictive for liver toxicity, especially Drug Induced Liver Injury (DILI). The MIP-DILI project will address this situation by the development of innovative preclinical liver test systems that are both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans. An iterative approach with respect to test compounds, test systems, bioanalysis and systems analysis will be adopted to evaluate existing models and develop new models that can provide validated test systems with respect to the prediction of specific forms of DILI. The applicability of hESC and hiPSC technology, including their utility as a source for hepatocytes will be tested. In collaboration with academic partners Cellartis will generate hiPSC-lines from DILI and non-DILI sensitive individuals. These lines will be characterised, expanded and banked, and will ultimately generate hepatocytes for use in this project. Human embryonic stem cells (hESC) have evolved as a powerful possibility for toxicity testing as they can be grown indefinitely and possess the capacity to differentiate into a broad range of cell types. They can be amplified to produce large quantities of differentiated cells and they remain the gold standard of pluripotent stem cells. Moreover, during the last three years, advances in cellular reprogramming have demonstrated that ectopic expression of defined transcriptional factors can cause human somatic cells to revert to a pluripotent state. These reprogrammed cells, human induced pluripotent stem cells (hiPSC) closely resemble hESC, and since they can be generated from theoretically any adult cell type they have the potential to represent an ideal source for generating patient-specific cells (DILI) for applications in this project. The acquisition of Cellartis is in line with Cellectis’ strategy to become the global market leader for stem cell-based in vitro models and related technologies. It makes it possible to considerably accelerate our development in this field. » said André Choulika, Chairman and CEO of Cellectis. About Cellectis stem cells: Cellectis stem cells speeds up the development of stem cell technology in particular to find a robust and reproducible way of controlling stem cell production and differentiation. Cellectis stem cells becomes a major, long-term and stable industrial player in the global marketplace. Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. For more information, visit www.cellartis.com About Cellectis Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE Euronext Paris Alternext market (code: ALCLS). To find out more, visit www.cellectis.com Disclaimer This press release and the information contained herein do not constitute an offer to sell or subscribe, or a sollicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above. For further information, please contact: Cellectis stem cells Cellartis AB Johan Hyllner Chief Scientific Officer +46 (0) 31 758 09 02 johan.hyllner@cellectis.com Cellectis Philippe Valachs Company Secretary +33 (0)1 81 69 16 00 media@cellectis.com Calyptus Alexis Breton / Cyril Combe +33 (0)1 53 65 68 68 cellectis@calyptus.net

companyNews - 23 February, 2012 - Isconova: Board Changes in Isconova AB

2012-02-24 18:07:47
The Board of Isconova thereby consists of: Russell G. Greig – Chairman of the Board Eva-Lotta Allan – Board member Gunnar Fernström – Board member Lars Gårdö – Board member Ulf Tossman – Board member Peter Wells – Board member Johan Rask – deputy Board member The Board intends to propose that Russell G. Greig continues in his position as Chairman of the Board at the upcoming Annual General Meeting on 10th May 2012. For more information, please contact: Ulf Tossman, resigning Chairman of the Board of Isconova AB Tel: +46 705-63 08 58 E-mail: ulf.innovative.advice@gmail.com About Isconova Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden. Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser. www.isconova.se Download PDF

companyNews - 23 February, 2012 - Isconova: Isconova appoints Sven Andréasson as new CEO

2012-02-24 18:03:56
Sven Andréasson has a strong background as a CEO for many years within both pharmaceutical and biotech companies; he was President & CEO of Active Biotech AB between 1999 and 2008. Prior to that he held several senior management positions within the international pharmaceutical industry, including as President and Vice President of mainly Swedish, French, Belgian and German companies in the Pharmacia Corporation. Sven has been appointed by the Board of Isconova with the main objectives of progressing key clinical studies, strengthening corporate development activities, and enhancing revenues from the current vaccine business. Ulf Tossman, Chairman of Isconova AB, commented; “Sven Andréasson has extensive industry experience from leading positions within the international pharmaceutical industry, including as President and CEO of Active Biotech. His business development skills, together with his proven track record for securing collaborations with international partners will be of great value to Isconova as we embark on the next stage of growth.” Sven Andréasson, incoming CEO of Isconova AB, commented; “Isconova’s proprietary Matrix M™ platform enabling technology has the potential to improve vaccines for both humans and animals, in an attractive, growing market where novel vaccines present a significant opportunity. The Company has a solid pipeline of early to late stage proprietary and partnered programmes and I look forward to being part of a strong management team to develop Isconova to its full potential.” Russell G. Greig has been appointed Chairman of the Board of Directors of Isconova – see separate release. For more information, please contact: Ulf Tossman, Chairman of the Board of Isconova AB Tel: +46 705-63 08 58 e-mail: ulf.innovative.advice@gmail.com Russell G. Greig, acting CEO and member of the Board of Isconova AB Tel: +1 610 220 9802 e-mail: russell.g.greig@gmail.com Sven Andréasson, incoming CEO of Isconova AB Tel: +46 701 60 60 60 e-mail: sven.andreasson@skynet.be About Isconova Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden. Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser. www.isconova.se Download PDF

companyNews - 13 February, 2012 - Oxeon: Oxeon explains how its TeXtreme spread tow fabrics are helping to reduce the weight of its customer, Shark Aero’s ultra light aircraft by optimising carbon reinforcement.

2012-02-14 18:28:31
Shark Aero, a new entrant for manufacturing premium European ULAs was established in 2008 to manage the production and sale of Shark aircraft. Based on the collaboration between the Gryf Design and Comp-Let in the MD-3 Rider aircraft development and is its logical continuation, the Shark aircraft combines the manufacturer’s experience with composites and the design team’s know-how gained during a large number of ULA designs. The company approached Oxeon in late 2008 when it began designing its first prototype ULA, and with a view to reducing weight on its composites parts in order to build faster aircraft. Speed and weight are key aspects to be kept in mind for designing the aircraft as an important goal is to reach the dream top speed of 300km/h for ULAs and to still keep the weight to a maximum of 300kg. Founded 2003 in Sweden, Oxeon has quickly established itself as one of the market leaders in spread tow carbon reinforcements. Their use is said to increase the mechanical performance of composite material products and reduce the weight. The company’s thin TeXtreme spread tow tapes are used to weave carbon fabrics with virtually no crimp to realise mechanical properties similar to a cross ply of uni-direction (UD). TeXtreme is based on combining two novel technologies: spread tow and tape weaving. First the carbon fibre tow is spread into thin flat spread tow tapes and then these spread tow uni-directional tapes are used to weave a spread tow fabric. The spread tow know-how Oxeon has recently introduced a groundbreaking innovation - the +α /-β variants of TeXtreme spread tow fabrics, with the initial offering of +45/-45 type. This proprietary process enables continuous-length production of novel fabrics by interlacing two sets of spread tow tapes in different angles +α/-β, for example +45/-45, +30/-60, +50/-25 etc. These fabrics complement the existing 0/90 type of TeXtreme to realise easily and quickly an optimised multidirectional reinforcement by direct plying. TeXtreme can be delivered both as dry fabric and as prepreg, which gives the manufacturers the opportunity to choose what is best suitable. Besides keeping the ULA within the weight restrictions, the main requirement for weight savings are that it enables many improved flight features. A lighter aircraft will normally have quicker reactions, and if you are lighter with identical aerodynamic configuration, then less power is needed to fly and consequently be more fuel efficient. When reducing weight, the payload is also improved, take-off and landing distance is reduced and the climb rate tends to be a little better as well. These flight features are all important aspects to deliver to the buyers of an ULA - and TeXtreme was chosen to accomplish this. Accordingly, a test programme was initiated in which Shark evaluated different TeXtreme variants and tested the mechanical properties of the resulting composite parts. Concluded in early 2010, the test programme clearly showed that the use of TeXtreme brought several mechanical and process advantages over the presently used materials in the industry. In particular, use of TeXtreme enabled composite parts to be redesigned to be significantly lighter without sacrificing on essential strength properties. Furthermore, the surface smoothness benefits of TeXtreme eliminated the need for using glass fabric as an outermost layer, whereby a laborious step in the manufacturing process was eliminated. Consequently, Shark Aero replaced its 200gsm and 90gsm fabrics with 160gsm and 80gsm TeXtreme fabrics respectively. “By changing to TeXtreme we saved an impressive 50kg in total,” explains Shark Aero’s CEO, Vladimir Pekar. “On average the weight of smaller parts such as the stabiliser, elevator, rudder, spinner and landing gear doors, have been reduced by 60%. Weight savings of this magnitude are paramount in this category of aircraft as it allows us to builder and foremost faster aircraft. Our aim is to use the best possible materials and TeXtreme qualifies for this.” Some light relief When producing Shark’s fuselage in series, it weighed 41kg, which is 25kg less than the 66kg prototype produced using conventional fabrics. “As a consequence of switching to TeXtreme and after recalculating the whole Shark fuselage with FEM, a saving of 25kg for the fuselage alone was very good as it was more than planned.” Pekar continues. “With such weight savings from use of TeXtreme, Shark Aero could meet the specifications demanding maximum empty weight of 300kg for a single seat ULA directly and at the same time improve many crucial flight features.” The significant reduction of crimp angle, the number of interlacing points and the thickness of spread tow fabrics uniquely contributes to improving the mechanical properties and fabric’s surface smoothness. Furthermore, due to smaller and fewer resin rich pockets in the final laminate, TeXtreme enables the final composite material product to have a smoother surface, something that the Shark aircraft have benefited from. “Another benefit besides the weight savings and surface smoothness is the ease of handling TeXtreme,” concludes Pekar. “It is really easy to work with TeXtreme and it only gets better when you get to know this new fabric.” With the help of these weight savings from TeXtreme’s spread tow reinforcement, Shark aircraft are presently up in the air and competing for world speed records with the aim of reaching the ultimate dream ULA limit of 300km/h in the very near future. www.oxeon.se Download documents - Oxeon

companyNews - 13 February, 2012 - Cellartis: CELLARTIS AB WILL BE A PARTNER IN THE 4DCELLFATE PROGRAM, AN EU-PROJECT AIMING TO BETTER UNDERSTAND STEM CELL DIFFERENTATION

2012-02-14 18:22:46
To develop a global understanding of the PRC and NuRD complexes in stem cell differentiation, in health and disease, the EU-project, 4DcellFate, aims to establish an integrated approach to explore the structure and function of the Polycomb Repressive Complexes (PRCs) and Nucleosome Remodelling and Deacetylation Complex (NuRD) in stem cell differentiation, and in cancer. Cellartis AB, Cellectis Stem Cells, will provide human embryonic stem cells (hESCs) to the program and will be involved in the development of methodologies for large scale proteomic analysis of the PRC and NuRD complexes during cell differentiation. Cellectis stem cells speeds up the development of stem cell technology in particular to find a robust and reproducible way of controlling stem cell production and differentiation. Through the sharing of knowledge and expertise developed by the two companies forming Cellectis stem cells - Cellartis and Ectycell – Cellectis stem cells becomes a major, long-term and stable industrial player in the global marketplace. Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. For more information, visit www.cellartis.com About Cellectis Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS). To find out more, visit www.cellectis.com Disclaimer This press release and the information contained herein do not constitute an offer to sell or subscribe, or a sollicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above. For further information, please contact: Cellectis stem cells Cellartis AB Johan Hyllner Chief Scientific Officer +46 (0) 31 758 09 02 johan.hyllner@cellectis.com Cellectis Philippe Valachs Company Secretary +33 (0)1 81 69 16 00 media@cellectis.com Calyptus Alexis Breton / Cyril Combe +33 (0)1 53 65 68 68 cellectis@calyptus.net

companyNews - 9 February, 2012 - Oxeon: Oxeon wins entrepreneur award

2012-02-14 18:10:42
The competition is known as the World Cup for entrepreneurs and this year Oxeon received an award from the Prince Daniel, Duke of Västergötland, at the award ceremony taking place in Stockholm the 8th of February. The jury’s motivation is: "By combining academic talent, strong entrepreneurial spirit and the old craft tradition, Henrik Blycker and Andreas Martsman have created a company that is growing at record speed. With a product that is found in both aircrafts as well as Formula 1 cars Henrik and Andreas are aiming at laying the composites market at their feet." This win follows a large number of prestigious awards earned by Oxeon, among others the “Supergasell” award as the fastest growing company in Sweden 2010. Henrik and Andreas comments the latest win: “We are very happy to have won this award, it is always positive to get recognition for the hard work we have put into the company for many years and keep on putting in. We feel that we have a great team and entrepreneurial spirit in place for taking Oxeon to new heights.” Oxeon produces, develops and markets TeXtreme® Spread Tow carbon reinforcements to companies in the composites industry looking for an optimized reinforcement solution. Images from the price award ceremony available under Images in the News Room. Press images of Henrik Blycker and Andreas Martsman and logos are available in the Press Room. About Ernst & Young Entrepreneur Of The Year Ernst & Young Entrepreneur Of The Year is one of the world's top awards for entrepreneurs. It is the first international award for entrepreneurs that with a clear vision and strong leadership skills build successful companies. The competition takes place at regional, national and international level in more than 140 cities in over 50 countries. The entrepreneurs are assessed by an external jury against the criteria entrepreneurial spirit, economic development, strategic direction, impact on the world, innovation and personal integrity and influence. The competition started in the U.S. in 1986. In Sweden the award began to be handed out in 1995 under the name Entrepreneur of the Year. Since 2001 the competition is called Ernst & Young Entrepreneur Of The Year. www.oxeon.se

companyNews - 8 february, 2012 - Isconova: Rabies Vaccines with Isconova’s Matrix-M™ adjuvant launched in Russia

2012-02-14 18:04:15
Since 2010 Isconova and VetBioChem, a leading Russian animal health company, have collaborated on the development of rabies vaccines for dogs and cats, and these vaccines, Rabix and Rabifel, are the first marketed veterinary vaccines using Isconova’s adjuvant Matrix-M™Vet. The agreement with VetBioChem includes revenues for Isconova for the supply of Matrix-M™Vet as well as royalties based on future sales of the rabies vaccines. Russell Greig, acting CEO of Isconova, commented; “We are very pleased that Rabix and Rabifel have been launched in Russia where rabies is a serious problem for both animals and humans. The launch of these Matrix-M™ based vaccines is further validation of our adjuvant technology platform and marks another step towards launching additional vaccines based on Isconova’s enabling technology in new markets.” For more information, please contact: Gerd Rundström, COO, Isconova AB Tel +46 18 16 17 06, e-mail: gerd.rundstrom@isconova.com About Isconova Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of vaccine systems, and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconova’s nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2006. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix M™. Isconova’s partners include Crucell/J&J, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden. Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s Certified Adviser. www.isconova.com About VetBioChem VetBioChem (NPO Narvac) is a leading animal health company in Russia. VetBioChem produces vaccines, diagnostics and therapeutics for cattle, pigs and companion animals. www.vetbiochem.com About Matrix-M™ Matrix-M™ is Isconova’s patented adjuvant for use in vaccines for humans and some animals, antibody production and immunological research. Matrix-M™Vet is used in animal vaccines. About adjuvants Adjuvants are substances that improve the efficacy and duration of protection of vaccines. Download

innkapNews - 6 February, 2012 - Inmeta Crayon: InnKap 4 Partners LP has sold its holding in Inmeta Crayon

2012-02-14 11:51:48
InnKap 4 Partners LP invested in Norwegian-based Crayon in 2008. Crayon provides services for managing corporate software and licenses and offers its customers IT consulting services and training. In early 2011, the company merged with Inmeta ASA, listed on the Oslo Stock Exchange. Following the merger, InnKap 4 Partners LP became one of the largest shareholders in Inmeta Crayon ASA. Metallic Invest AS, a holding company owned by funds managed by the Norwegian private equity company Norvestor Equity AS, made a public offer to acquire Inmeta Crayon on 14 December 2011. The offer was accepted with a sufficient majority of InmetaCrayon’s shareholders during January 2012. Consequently, InnKap 4 Partners Ltd sold its shares in Inmeta Crayon and made a final exit from the company. The settlement of the transaction took place on 27 January 2012. The fund‘s ownership in Inmeta Crayon was approximately 9.5%. Further information: Martin Falkevall, Investment Director, InnovationsKapital tel. +46 8 54501496 InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 70 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Cellartis, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 26 January, 2012 - Xtract: Comptel takes next steps in executing its strategy by acquiring leading analytics company Xtract

2012-02-06 13:42:42
Comptel Corporation is acquiring Xtract Oy, a Finnish software company specialising in advanced analytics, for a total consideration of EUR 3.1 million (enterprise value). Xtract has approximately 20 customers including telecom operators AVEA in Turkey, DNA in Finland, Megafon in Russia and TeliaSonera in Finland as well as insurance company If, retail and media companies. Xtract’s net sales were EUR 2.4 million in 2011. Xtract has 27 highly skilled employees which are mainly based in Espoo, Finland. The transaction is estimated to close in mid-February 2012 from which time onwards Xtract Group will be consolidated into Comptel Group financials. The acquisition is financed through Comptel Corporation's liquid assets. The main selling shareholders are private equity funds managed by Creandum, Innovations Kapital and Verdane. Comptel’s strategy is around building an integrated offering for service providers to manage the customer experience and to drive new revenues from their subscriber base. Comptel has a world leading platform for information extraction and automated service fulfillment with 280 customers worldwide. By acquiring Xtract the company will create a unique offering by combining world class analytics capabilities with its existing assets. This offering will enable operators to react quickly to events from the network and transform them automatically into relevant and timely actions that improve the customer experience. “Xtract is globally a leading expert in advanced customer analytics. This acquisition completes Comptel’s ‘event-analysis-action’ vision, which will help telecom operators provide value to their customers and operations by driving real-time business decisions. Delivering on this vision is a key for our growth in our recently communicated strategy”, comments Mr Juhani Hintikka, President and CEO of Comptel. COMPTEL CORPORATION Juhani Hintikka President and CEO Additional information: Juhani Hintikka, tel. +358 9 700 1131 For financial analysts, investors and media Comptel will arrange an English speaking teleconference on the acquisition today 26 January at 13.30 pm Finnish time (11.30 am UK time). The dial-in number for a local call in Finland is 0923 195 187, UK local call 0844 493 3800, US local call 1631 510 7498 and internationally +44 (0) 1452 555 566. Conference ID is 46206779. Distribution: NASDAQ OMX Helsinki Major media Comptel software solutions and services enable telecom operators to deliver services flexibly and charge them effectively. Comptel's wide expertise in service fulfillment, mediation and charging empowers customers to focus on delivering innovative services. Comptel has provided solutions to 280 service providers with more than one billion subscribers in 85 countries. The Group has about 600 employees worldwide, and net sales were EUR 78 million in 2010. www.comptel.com

innkapNews - 8 December, 2011 - Inmeta Crayon: Inmeta Crayon ASA : Recommended voluntary cash offer to acquire 100% of Inmeta Crayon ASA

2012-01-03 16:36:40
The Offeror and Inmeta Crayon have entered into a transaction agreement regarding an acquisition of Inmeta Crayon by the Offeror. Under the terms of the agreement, the Offeror will put forward a recommended voluntary cash offer (the "Offer") for all of the shares of Inmeta Crayon. The consideration offered will be NOK 6.00 in cash per Inmeta Crayon share. This represents a premium of approximately 46 % to the closing share price of Inmeta Crayon on 7 December 2011, the last trading day prior to the announcement of the Offer and a premium of approximately 50 % to the one month volume weighted average share price of Inmeta Crayon for the period ended on 7 December 2011. The Offer values the total share capital of Inmeta Crayon at approximately NOK 831 million. The Offeror is not obliged to launch the Offer if EUR has depreciated by more than 5% against NOK at any time before 12:00 CET on 12 December 2011 compared to the EUR/NOK exchange rate at 18:00 CET on 8 December 2011. The Offeror is a special purpose vehicle currently owned by Norvestor V, LP and Norvestor V SBS, LP, acting by their general partner Norvestor V General Partner LP, acting by its general partner Norvestor V (GP) Limited. Norvestor V L.P. is a private equity investment fund with a capital base of approximately EUR 236 million. The fund's objective is to invest in strong growth companies in the Norwegian and Nordic market. After having reviewed the terms and conditions of the Offer, the Board of Directors of Inmeta Crayon is of the view that an acceptance of the Offer is in the best interest of the Company's shareholders. The Board has received a fairness opinion dated 7 December 2011 from First Securities AS. First Securities AS' fairness opinion provides that, as of the date thereof and based upon the information available per 7 December and subject to the assumptions, considerations, qualifications, factors and limitations set forth therein, First Securities is of the opinion that the Offer Price is fair and on market terms. The Fairness Opinion is subject to change in case of new material information. Management and other employees of Inmeta Crayon holding shares in the Company (the "Management Investors") have entered into an investment agreement with the Offeror, whereby the Management Investors will, conditional upon completion of the Offer and otherwise subject to customary conditions, transfer Inmeta Crayon shares owned by them representing approximately 36 % of the total share capital of Inmeta Crayon to the Offeror. Other shareholders representing approximately 5 % of the total share capital of Inmeta Crayon have already given their pre-acceptances to the Offer, subject to customary conditions. The shares to be transferred by the Management Investors to the Offeror, conditional upon the completion of the Offer, and the shares subject to the irrevocable pre-acceptances represent in aggregate approximately 41 % of the total share capital of Inmeta Crayon. Jarl Øverby, CEO of Inmeta Crayon, said, "We believe Norvestor will be a good new owner for Inmeta Crayon in order to help us to strengthen our positions in existing markets and to accelerate our plans to enter new markets. We look forward to embarking on a new journey together with Norvestor." Henning Vold, Partner in Norvestor Equity AS, said, "We have followed both Inmeta and Crayon for many years and we are impressed by the results achieved by management. We are excited about the opportunity to assist the company in its future development." The Offer will not be subject to any financing or due diligence conditions. The complete details of the Offer, including all terms and conditions, will be contained in an Offer Document to be sent to Inmeta Crayon shareholders following review and approval by the Oslo Stock Exchange pursuant to Chapter 6 of the Norwegian Securities Trading Act. As will be further detailed and specified in the Offer Document, the completion of the Offer will be subject to the following conditions being satisfied or waived by Offeror: (i) the Offer shall have been accepted by shareholders of Inmeta Crayon representing (when taken together with any shares acquired or agreed to be acquired by the Offeror other than through the Offer) more than 90 % of the issued and outstanding share capital of Inmeta Crayon, (ii) all approvals required from regulatory authorities for completion of the Offer shall have been obtained, (iii) all required third party approvals have been obtained, (iv) there having occurred no material adverse change, as defined in the transaction agreement, with respect to the Company and its subsidiaries, taken as a whole, (v) the Board of Inmeta Crayon shall not have amended or withdrawn its recommendation of the Offer, (vi) no intervention shall have taken place by any court or other governmental or regulatory authority which restrains or prohibits the completion of the Offer, and (vii) there shall have been no breach by Inmeta Crayon of the transaction agreement which entitles Offeror to terminate the transaction agreement. The Offeror is in the process of preparing an Offer Document which has been filed with the Oslo Børs. The Offer Document will be sent to Inmeta Crayon's shareholders as soon as it has been approved by Oslo Børs. Such approval is expected on or before 16 December 2011. The acceptance period for the Offer will be two weeks from the date of the Offer Document being released, unless extended by the Offeror. The Offer will not be made in any jurisdiction in which the making of the Offer would not be in compliance with the laws of such jurisdiction. This notification does not in itself constitute an offer. The Offer will only be made on the basis of the Offer Document and can only be accepted pursuant to the terms of such document. SEB Enskilda is acting as financial adviser to the Offeror in connection with the Offer. ABG Sundal Collier is acting as financial adviser to Inmeta Crayon in connection with the Offer. For further information, please contact: Henning Vold (Chairman of the Board of Metallic Invest AS) +47 90 87 95 81 henning.vold@norvestor.com Paal S. Raaholt (Chairman of the Board of Directors of Inmeta Crayon) +47 92 62 73 00 psr@inmeta.com Jarl Øverby (CEO of Inmeta Crayon) +47 98 21 70 09 jarl.overby@inmeta.com About Offeror The Offeror is a special purpose vehicle currently owned by Norvestor V, LP and Norvestor V SBS, LP, acting by their general partner Norvestor V General Partner LP, acting by its general partner Norvestor V (GP) Limited. Norvestor V L.P. is a private equity investment fund established on Guernsey with a capital base of approximately EUR 236 million. The fund`s objective is to invest in strong growth companies in the Norwegian and Nordic market. About Inmeta Crayon Inmeta Crayon focuses on advising enterprises with complex IT needs. The business focus is on software licence advisory, courses and consulting services. Inmeta Crayon has about 470 employees, and is present in Norway, Sweden, Denmark, Finland and Germany. Licensing provides licence advice to optimise commercial and legal terms in standard software contracts which ensure control, flexibility and cost savings for enterprises. Consulting provides IT consulting services for major enterprises. Technological knowledge combined with wide experience of selected sectors, solutions and project execution mean the consultancy business is well positioned in a developing market. Inmeta Crayon's revenues amounted to approx. NOK 1.5 billion in 2010, with an EBITDA of NOK 70 million (pro forma). The company is listed on the Oslo Stock Exchange (ticker is INM). This information is subject to the disclosure requirements according to Section 5-12 of the Norwegian Securities Trading Act. The Offer and the distribution of this announcement and other information in connection with the Offer may be restricted by law in certain jurisdictions. Offeror assumes no responsibility in the event there is a violation by any person of such restrictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Inmeta Crayon ASA via Thomson Reuters ONE www.inmetacrayon.com

innkapNews - 2 november, 2011 - Cellectis: Cellectis shareholders approve the acquisition of Cellartis. Cellectis decides to raise €50 million from the FSI and Mr. Pierre Bastid, and to grant free share purchase warrants to all existing shareholders.

2011-11-24 12:46:45
More specifically, Cellectis’ shareholders approved the following resolutions: • Operational takeover of Cellartis by Cellectis. In return for selling 100% of Cellartis’ capital, Cellartis’ shareholders will receive 1,933,333 Cellectis shares1 and €16.4 million in cash, subject to final completion of the €50 million financing round, • Appointment of Mr. Laurent Arthaud as a director, representing the FSI, replacing Mr. Richard Mulligan, following the latter’s resignation, and two new independent directors, Mrs. Annick Schwebig and Mr. Pierre Bastid, subject to final completion of the €50 million financing round. In addition, at the Board meeting held today following the shareholders’ meeting, the directors decided, upon delegation of the shareholders’ meeting, to: • Issue 6,250,000 convertible bonds at a price of €82 to be subscribed evenly by the FSI and Mr. Pierre Bastid (i.e. €25 million each), and • Grant share purchase equity warrants to Cellectis’ existing shareholders (not including the FSI, Mr. Pierre Bastid and Cellartis’ shareholders) on the basis of one share purchase warrant for each currently held share, with five share purchase warrants entitling their holder to subscribe for one new share at a price of €93, in order to enable them to participate in the Company’s development and limit the impact of the dilution relating to the acquisition of Cellartis and the new financing round. The free share purchase warrants will be granted on November 1st, 2011 to all of the Company’s shareholders based on the Euroclear France positions at October 31st, 2011. Subject to final completion of the acquisition of Cellartis and the new financing round, both to be carried out by November 4th, 2011, the share purchase warrants will be registered for trading on the Alternext market of NYSE Euronext Paris on November 7th, 2011 and could be exercised from the same day until October 28th, 2014. Not for release, publication or distribution, directly or indirectly, in Australia, Canada, Japan or the United States PAI-658667v6 A press release announcing the final completion of the acquisition of Cellartis and the new financing round4 will be published by the Company on November 4th, 2011. On October 28th, 2011, the French financial market authority (Autorité des marchés financiers, the “AMF”) granted visa number 11–488 to the prospectus relating to the allocation of the free share purchase warrants, comprising the reference document registered by the AMF on October 24th, 2011 under number R. 11-059 and a note d’opération (including the prospectus summary). The prospectus is available free of charge from Cellectis, 8, rue de la Croix Jarry, Paris 75013, France, and from Bryan, Garnier & Co., 26, avenue des Champs Elysées, 75008 Paris, France. It may also be downloaded from the Cellectis (www.cellectis.com) and AMF (www.amf-france.org) web sites. Cellectis would like to draw the public’s attention to the sections relating to the risk factors set forth in the prospectus approved by the AMF. If all or part of such risks were to occur, this might have a material adverse effect on the Company’s business, earnings, financial situation and prospects. André Choulika, Chairman and CEO of Cellectis: "The acquisition of Cellartis is in line with Cellectis’ strategy to become the global market leader for stem cell-based in vitro models and related technologies. It will make it possible to considerably accelerate our development in this field, while enhancing our commercial offers which are revolutionizing research and development for new applications across all life science industries. This major strategic step forward will all the more strengthen Cellectis’ potential that it is supported by the arrival of two reference shareholders. The FSI and Pierre Bastid represent decisive assets in terms of our goal to become one of the European life sciences industry leaders within five years". * * * About Cellartis Formed as a spin-off from the University of Gothenburg, Cellartis is a Swedish company with 10 years’ active experience in the development, industrialization and marketing of stem cell-derived cardiomyocytes and hepatocytes. Currently, these differentiated cells are mainly used for research and pharmaceutical clinical trials, and they offer unrivalled performance in toxicity testing. Cellartis’ unique position is based on its ownership and exploitation of the largest stem cell bank in the world (30 proprietary lines) and on the expertise in differentiation technologies that the company has developed since it was set up. The industrial rollout of these technologies has led to the creation of two certified sites in Sweden and Scotland. Alongside leading partners, Cellartis is involved in regenerative medicine programs which use the immense potential of stem cells for the restoration of damaged tissues and organs. Cellartis has 62 employees, all with a high level of scientific and industrial expertise. The company’s turnover in 2010 was €3 million. At June 30th, 2011, it had SEK 2.6 million in shareholders’ equity, SEK 7.5 million in net cash and zero financial debt (unaudited figures). For more information, please visit www.cellartis.com. About the FSI The FSI (Fonds Stratégique d’Investissement or Strategic Investment Fund) is a French limited company (société anonyme) owned by the Caisse des Dépôts (51%) and the French state (49%). It acts as an informed investor, taking minority stakes in promising French companies and industrial projects that create value and boost the competitiveness of the country’s economy. For more information, please visit www.fonds-fsi.fr. About Pierre Bastid Pierre Bastid is a French industrialist, and former Chairman of Converteam, the company he acquired from Alstom in 2005 with backing from investment funds and sold to General Electric in September 2011. Pierre Bastid will now be focusing on private investment, primarily targeting high-potential companies in emerging industries. About Cellectis Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, biological research and agriculture. Cellectis is listed on the NYSE-Euronext Paris Alternext market (code: ALCLS). For more information, please visit www.cellectis.com. Not for release, publication or distribution, directly or indirectly, in Australia, Canada, Japan or the United States PAI-658667v6 1 Representing a dilution of approximately 13.1% for existing shareholders on a fully diluted basis and before the conversion of the convertible bonds issued to the FSI and Pierre Bastid. 2 Representing a dilution of approximately 33% for existing shareholders, and an equity share of approximately 16.5% for each new investor, on a fully diluted basis after redemption of the convertible bonds, assuming that this redemption is based on a price of €8 per share (one share per convertible bond). The convertible bonds will include a coupon of 3.40% and will be redeemed early if Cellectis’ share price exceeds €8 for three consecutive trading days. Otherwise, their share redemption ratio, initially set at one share per convertible bond, could be adjusted upwards (maximum adjustment up to the reference share price retained for the issue) if the share price at maturity (three years) is below €8. 3 Representing 2,439,022 new shares if all the share purchase warrants are exercised, enabling the existing shareholders’ to increase their shareholding of up to approximately 10% on a fully diluted basis following the acquisition of Cellartis and the new financing round, assuming that the convertible bonds issued are subsequently converted into capital at a price of €8 per share. 4 Or, as the case may be, their postponement, as well as the postponement of the beginning of the exercise and trading periods of the share purchase warrants. Disclaimer This press release and the information contained herein do not constitute an offer to the public, an offer to subscribe, or the solicitation of the public in view of an offer of securities to the public. No offer of securities to the public will be made inside or outside France until a prospectus within the meaning of Directive 2003/71/EC is approved by the French Autorité des marchés financiers (AMF). The distribution of this press release in certain countries may be subject to specific regulations. This press release shall not be published, released or distributed, directly or indirectly, in Australia, Canada, Japan or the United States of America. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy securities of Cellectis in Australia, Canada, Japan, the United States or any other country. The shares, share purchase warrants, shares issuable upon exercise of the share purchase warrants, the convertible bonds and the shares issuable upon exercise of the convertible bonds of Cellectis (the “Securities”), if and when issued, may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933 as amended. The Securities have not been and will not be registered under the U.S. Securities Act and Cellectis does not intend to conduct a public offering of any of such Securities in the United States. This press release contains forward-looking statements, including statements about Cellectis’ business and prospects, its acquisition of Cellartis, and a potential offering of its Securities. Such forward-looking statements are based on data, assumptions and estimates that Cellectis considers to be reasonable. They are subject to numerous risks and uncertainties, including matters not yet known to Cellectis or not currently considered material by Cellectis, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in forward-looking statements include, among others, the development of economic conditions, financial markets and the markets in which Cellectis operates. For further information, please contact: Cellectis Philippe Valachs Company Secretary Tel: +33 (0)1 81 69 16 00 media@cellectis.com Marc Le Bozec Chief Financial Officer Tel: +33 (0)1 81 69 16 00 investor@cellectis.com Calyptus Alexis Breton / Cyril Combe Tel: +33 (0)1 53 65 68 68 cellectis@calyptus.net

innkapNews - 15 September, 2011 - Cellartis: SWEDISH STEM CELL COMPANY CELLARTIS TO BE ACQUIRED BY FRENCH BIOTECH COMPANY CELLECTIS

2011-10-05 11:46:13
“We are extremely delighted to take the next transformative steps and continue to build on our stem cell platform together with Cellectis" said Johan Hyllner, CEO of Cellartis. “In my opinion, the deal represents a giant leap forward in creating a strong industrial corporation, encompassing many new innovations and entering the stem cell and regenerative medicine arena.” “We are enthusiastic to have the opportunity to combine Cellartis’ world-renowned expertise in pluripotent stem cells-based industrial applications with Cellectis’ highend genetic engineering platform. Together, we will be in a position to accelerate the development of stem cell based solutions including therapies targeting diseases reputed as incurable thanks to regenerative medicine”, underlines Gunnar Fernström, Chairman of Cellartis, adding he is “convinced that the industrial platform and the stem cell- based products developed by Cellartis during the last decade are very valuable assets which will significantly contribute to the creation of a world leader in stem cells”. “The acquisition of Cellartis demonstrates our will to accelerate our development via targeted, relevant external growth operations” declares André Choulika, co Founder, Chairman and CEO of Cellectis. “At Cellectis, we are very pleased to continue to build on Cellartis’ unique stem cell platform in synergy with our genome editing technology.“ In return for the full divestment of their stake, Cellartis shareholders will receive 16.4 million euro in cash and 1.93 million Cellectis shares. Danske Bank Corporate Finance and Advokatfirman Vinge are acting as advisors to Cellartis and its owners on this transaction. Cellartis Enquiries: Dr. Johan Hyllner Chief Executive Officer (+46) 317580902 johan.hyllner@cellartis.com Gunnar Fernström Chairman of the Board (+46) 31609192 gunnar.fernstrom@innkap.se About Cellartis: Cellartis AB is a premier provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the world's largest single commercial source of ethically derived hES cell lines and has developed more than 30 cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001, has over 60 employees and is located in Gothenburg, Sweden and Dundee, Scotland, UK. For more information, please visit www.cellartis.com About Cellectis: Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. For further information about Cellectis, please visit: www.cellectis.com Follow Cellectis on twitter: twitter.com/cellectis

innkapNews - 31 May, 2011 - Ignis: InnKap 3 Partners have sold the shareholding in Ignis ASA

2011-06-01 16:57:50
Finisar Corporation has now successfully completed its voluntary public cash offer to acquire the outstanding shares of Ignis ASA, a Norwegian company whose shares are listed on the Oslo Stock Exchange (OSE: IGNIS), at a cash price of NOK 8 per share. Since April 2009, InnKap 3 Partners have been a shareholder in Ignis ASA. InnKap 3 Partners became a shareholder in Ignis through the sale of Syntune AB to Ignis. Ignis ASA is an innovative provider of optical components and network solutions for fiber optic communication. Stockholm May, 2011 For more information, please contact: Peder Holm, Investment Director, InnovationsKapital, +46 8 54 50 14 93, +46 703 46 57 70, peder.holm@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 70 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, Nor dNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 13 May, 2011 - InnovationsKapital: InnKap 4 Partners L.P. acquires stake in Paxport

2011-05-13 13:57:47
Paxport enables the charter airline business to move as the banking industry has done, allowing the passenger to do more themselves while adding value to the booking process. This reduces cost and enables higher levels of utilisation & efficiency in the industry. Paxport’s product and service platform is proprietary and developed in house. The business model is based on an outsourcing or software as a service concept where Paxport becomes a strategic partner on a revenue share model. The risk to the customer, set up and fixed costs are minimal and their operational needs are managed by Paxport. Paxport also turns certain regulations into sales opportunities such as check-in and security requirements. “We are very pleased to have InnKap 4 Partners as a new shareholder. We see no changes in our current strategy, but InnKap will add momentum and help us speed up the development to satisfy our customers’ needs”, says Patrick Lindblom, CEO at Paxport. InnovationsKapital invests in Nordic technology companies with strong growth. “For InnKap 4 Partners, Paxport offers the opportunity to become an owner in a well managed growth company that is pioneering the market with its ancillary revenue platform for the leisure travel industry in Europe”, says Peder Holm, responsible for InnovationsKapital’s investment in Paxport. For more information, please contact: Patrick Lindblom, CEO, Paxport +46 70 322 55 85 patrick.lindblom@paxport.se Peder Holm, Investment Director, InnovationsKapital +46 8 54 50 14 93 +46 703 46 57 70 peder.holm@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 70 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 25 February, 2011 - InnovationsKapital: InnovationsKapital’s fund, InnKap 3 Partners, and other owners of Jolife AB have signed an agreement to sell their shareholding in Jolife to Medtronic, one of the world’s leading medical technology companies.

2011-02-25 16:27:36
Founded in 2000, Jolife AB develops and manufactures the LUCAS Chest Compression System, a medical device for heart-lung-resuscitation. Jolife’s vision is to save more lives and to increase the quality of life of sudden cardiac arrest victims. InnovationsKapital made its initial investment in Jolife, together with CapMan-managed fund Swedestart Life Science, in 2003. Jolife is located in Lund in Southern Sweden and employs 21 people. “We are pleased that Medtronic, a clear leader in the resuscitation space, has recognized the potential of Lucas® and Jolife. This is a proof that Swedish medical technical research is world leading and through this transaction Swedish innovation gets a global distribution. Jolife’s management and personnel have done an excellent job to reach the position of today. ”, says Ulf Tossman at InnovationsKapital. Prior to the transaction InnKap 3 Partners owned 20 % of the shares in Jolife AB.

innkapNews - 9 February, 2011 - InnovationsKapital: Emric acquires Financial Systems - is now the biggest IT supplier in the Nordic region within credit financing

2011-02-14 12:17:47
During 2010 Emric achieved sales of SEK 92 million, while Financial Systems reached SEK 55 million (preliminary figures). The acquisition means that the company now has customers in more than 20 countries.
“The acquisition provides us with much greater expertise within e.g. leasing, and it accelerates our international expansion, even though the Nordic region will continue to be our primary market,” comments Joakim Dahlgren, Emric’s CEO.
The newest – and largest – owner in the new company is InnovationsKapital, with a shareholding of 26%.
“Emric enjoys an extremely strong position in its market, and we are optimistic about the company’s opportunities for continued growth not only in the Nordic region, but also internationally,” adds Peder Holm, Investment Director at InnovationsKapital.
Emric plans to recruit 10 or more additional employees during 2011. Among its customers are many banks and credit institutions in the Nordic market such as Danske Bank, Länsförsäkringar bank, Handelsbanken, ICA Banken, Nordea, SBAB, SEB, Swedbank and Xerox.
“Our roots are in software development but we are becoming more and more of a total partner for our customers in everything that concerns their credit processes. The credit process takes far too much time at many credit institutions and this costs customers a lot of money. By using smarter processes and more efficient systems we can achieve great savings, as can our customers,” states Joakim Dahlgren.
For further information, please contact: Joakim Dahlgren, Group CEO and CEO at Emric Tel: +46 8 400 28 400, Mob: +46 70 979 0305 joakim.dahlgren@emric.com About Emric Emric offers banks and credit institutions business expertise, outsourcing and systems support for the various stages of the credit process. The company’s history stretches back to Öhman’s investment bank founder Emric Öhman. Öhman Financial Systems became Emric in 2001 and since then annual sales have increased from SEK 24 million to SEK 92 million today (2010). www.emric.se For further information, please contact: Peder Holm, Investment Director, InnovationsKapital, +46 31 60 91 90 peder.holm@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 9 Januari, 2011: InnovationsKapital: Emric förvärvar Financial Systems AB -blir största IT-leverantören i Norden inom kreditgivning

2011-02-11 11:29:44
Under 2010 omsätter Emric 92 miljoner kronor och FSAB omsätter 55 miljoner kronor (preliminära siffror) Efter förvärvet har företaget kunder i över 20 länder.

Förvärvet ger oss mycket djupare expertis inom bland annat leasing och det påskyndar vår internationella expansion, även om Norden fortsätter att vara vår primärmarknad, kommenterar Joakim Dahlgren, VD på Emric.
Ny och tillika största ägare i det nya bolaget är InnovationsKapital som äger 26%.
Emric har en mycket stark position på sin marknad och vi är optimistiska kring bolagets möjligheter att fortsätta växa i såväl Norden som internationellt, kommenterar Peder Holm, Investment Director, InnovationsKapital.
Emric planerar att rekrytera ytterligare ett tiotal nya medarbetare under 2011. Bland kunderna märks flertalet banker och kreditinstitut på den Nordiska marknaden såsom Danske Bank, Länsförsäkringar bank, Handelsbanken, ICA Banken, Nordea, SBAB, SEB, Swedbank och Xerox.
Vi har vårt ursprung i mjukvaruutvecklingen men vi blir allt mer av en helhetspartner till våra kunder i allt som rör deras kreditprocesser. Hos många utlåningsföretag tar kreditprocessen alldeles för lång tid och det kostar dem mycket pengar. Genom smartare processer och effektivare system kan vi uppnå stora besparingar tillsammans med våra kunder, menar Joakim Dahlgren.
För mer information vänligen kontakta: Joakim Dahlgren, Koncernchef och VD på Emric +46 8 400 28 400 joakim.dahlgren@emric.com Om Emric Emric erbjuder banker och kreditgivare verksamhetskompetens, outsourcing och systemstöd för de olika stegen i kreditprocessen. Företagets historia går tillbaka till investmentbanken Öhmans grundare, Emric Öhman. Öhman Financial Systems blev Emric 2001 och sedan dess har omsättningen ökat från 24 miljoner kronor till 92 miljoner kronor (2010). www.emric.se För mer information vänligen kontakta: Peder Holm, Investment Director, InnovationsKapital, +46 31 60 91 90 peder.holm@innkap.se InnovationsKapital InnovationsKapital, som grundades 1994, är ett ledande venture capital bolag som investerar i unga, innovativa tillväxtföretag i Norden. Verksamheten bedrivs via kontor i Göteborg och Stockholm och fokuserar på Nordiska investeringar i ICT och Healthcare & Life Scieneces – dynamiska sektorer som är starkt växande och där nordisk forskning och utveckling har en framträdande plats. InnovationsKapital är rådgivare till fyra fonder som sammanlagt har 323 MEUR i förvaltat kapital från både svenska och internationella investerare. Ytterligare information finns på www.innkap.se

innkapNews - 18 October, 2010 - InnovationsKapital: InnKap 4 Partners L.P. acquires stake in Oxeon AB

2010-10-18 14:56:33
Founded in 2003, Oxeon has quickly established itself as the market leader in Spread Tow reinforcements. Use of these Spread Tow carbon reinforcements increases the mechanical performance of composite material products and reduces the weight. Utilization of Oxeon’s TeXtreme® Spread Tow Fabrics and TeXero® Spread Tow Tapes by manufacturers of advanced aerospace, automotive, racing, industrial and sports products in applications that have critical material performance requirements has affirmed the significance of Oxeon’s ultra light materials. InnovationsKapital invests in Nordic high-tech companies with strong growth. “Oxeon AB is a very exciting company with a unique product offering and with impressive customer traction. The company has a strong management team and we see this as a great opportunity to invest in a company with good growth and profitability”, says Staffan Ingeborn, responsible for InnovationsKapital’s investment in Oxeon. For more information, please contact: Staffan Ingeborn, Managing Director, InnovationsKapital, +46 31 60 91 90 staffan.ingeborn@innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 24 March, 2010 - InnovationsKapital: InnKap 4 Partners LP invests SEK 29.5 million in Gammadata AB to acquire shares and establish a long-term relationship

2010-06-10 09:47:43
Gammadata Group is established as a leader in the three areas of operations and serve customers across the globe. “We are very pleased to have InnKap 4 Partners as a new owner. We expect InnKap to support our promising plans, and to help us to take Gammadata forward”, says Jan Edhäll, CEO at Gammadata. InnovationsKapital invests in Nordic high-tech companies with strong growth. “Gammadata is a very interesting company with a unique product offering based on Nobel price winning technology. The company has a strong management team and we see this as a great opportunity to invest in a company with good growth, profitability and cash generation”, says Martin Falkevall, responsible for InnovationsKapital’s investment in Gammadata. For more information, please contact: Jan Edhäll CEO, Gammadata +46 18 480 58 00 www.gammadata.se Martin Falkevall Investment Director, InnovationsKapital +46 8 545 014 90 mf@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 23 April, 2010 - InnovationsKapital: The best investment of all time - InnovationsKapital and CapMan (Swedestart) for Altitun AB

2010-05-06 16:07:54
A new prize is instituted specifically for SVCAs 25th anniversary rewarding a private equity firm that has made an exceptionally successful investment. Motivation: An investment in a small seed company with negative cash flow came to be a jackpot for the entrepreneurs and investors when the company after a great journey got acquired by an industrial partner. The active ownership by private equity firms, combined with the portfolio company's unique high-tech competence came to be a success story that became a symbol of good entrepreneurship, innovation and commercialization. At the acquisition the VCs received incredible 87 times the money. The deal turned out to be glorious also for the Swedish taxpayers having invested in the research in the company. The sale of the company meant tax revenue to the Swedish state of entire SEK 1 billion. For further information, please contact: Staffan Ingeborg, Investment Director, InnovationsKapital +46 70-583 14 34 staffan.ingeborn@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 5 February, 2010 - InnovationsKaptial: Wind River to Add Virtutech Simics Products to Comprehensive Embedded Software Portfolio

2010-02-26 10:23:16
Wind River will sell and support Virtutech’s flagship development platform, Simics, as a stand-alone product and will continue to support all current architectures including ARM, Intel, MIPS and PowerPC. Simics will allow Wind River to offer a market-leading virtual systems development solution in a growing market segment of virtualization and simulation tools for device software development. “The addition of Virtutech’s development platforms to our product line will allow Wind River to offer greater value to customers across the entire product lifecycle and deepen current relationships with our broad set of silicon partners,” said Ken Klein, president, Wind River. “Time-to-market remains the single most challenging issue that sophisticated electronic equipment manufacturers need to address and ultimately control in order to remain competitive. With the addition of the Simics products, Wind River adds a key solution to further help customers improve time-to-market, as system complexity and ever more stringent demands upon overall system quality rapidly increase.” “Through our long-standing partnership with Wind River, it became evident that both companies shared a vision of how we can help the electronic systems market rethink how it goes about complex product development by deploying virtual platforms,” said John Lambert, CEO, Virtutech. “Time and again, Virtutech has helped customers and partners improve time-to-market by enabling the full sweep of systems development activities to take place on a virtual platform, freeing them up to apply new and innovative ways of running systems development projects. By combining with Wind River, we now have the opportunity to dramatically accelerate the spread of this key market trend and to bring the benefits of virtual platforms to a broader audience.” Simics provides binary-compatible hardware simulations that operate completely within a virtualized environment running on standard laptop or desktop PCs. This strategy allows OEMs to undertake critical software development activities on a virtual platform, independently of any hardware development schedules, semiconductor availability constraints or other limitations. This also allows semiconductor manufacturers to redefine complex system-on-chip development with greater ecosystem support and customer engagement. Virtutech therefore enables customers to manage complexity, drive improved quality and achieve higher productivity, all while lowering capital expenditure and shortening total development time. Acquired by Intel last year, Wind River develops operating systems, middleware (software found between an OS and software application), and software design tools for a variety of embedded computing systems. Its main products include VxWorks, the market-leading proprietary and multicore-ready real-time operating system, and commercial-grade Linux software platforms. The company also provides design services and software expertise, including custom-built solutions, development tools and device testing products. With thousands of customers, Wind River technology is relied upon by most major computer and networking communications companies, and is used by corporations and government agencies such as Alcatel-Lucent, BMW, Boeing, Bombardier Transportation, Mitsubishi, Motorola, NASA, Sony, Verizon and many more. Intel’s acquisition of privately-held Virtutech is expected to be completed this quarter. Terms of the deal are not being disclosed. About Virtutech Virtutech, Inc. is the leader in product development process improvement through virtualized systems development (VSD). Virtutech Simics® allows for a revolutionary change in the product development process at a full system level rather than a component level and is a commercial solution that uniquely delivers the four most important criteria for successful deployment of hardware virtualization in the electronics equipment development process: speed, scalability, model availability, and control. Simics customers report reduced time to market, better project risk management, lower capital expenditure, product development cost and maintenance as well as increased quality and individual productivity. Virtutech serves the needs of the world’s leading OEMs in the high-performance computing, aerospace and defense, telecommunications, networking and semiconductor industries. Customers include Cisco, Ericsson, Freescale Semiconductor, GE Avionics, Honeywell, IBM, Lockheed Martin, Nortel and Northrop Grumman. Virtutech is an active participant in organizations to drive adoption of VSD such as ARM Connected Community, Eclipse.org, IBM PartnerWorld, Multicore Association, Power.org, OSCI and Spirit Consortium. For more information, visit www.virtutech.com About Wind River Wind River, a wholly owned subsidiary of Intel Corporation (NASDAQ: INTC), is a world leader in embedded and mobile software. Wind River has been pioneering computing inside embedded devices since 1981 and its technology is found in more than 500 million products. Wind River is headquartered in Alameda, Calif. with offices in more than 15 countries. To learn more, visit Wind River at www.windriver.com or blogs.windriver.com CONTACTS Bryan Thomas Wind River Tel: +1 510-749-2414 bryan.thomas@windriver.com

innkapNews - 18 December, 2009 - InnovationsKapital: Microdata raises 10 million SEK to fund international expansion

2010-01-18 16:39:07
Microdata Telecom Innovation AB is raising 10 million SEK from venture capital firm InnovationsKapital and from existing shareholders through an equity issuance. Microdata Telecom is currently expanding internationally to address a rapidly growing global market for Microdata Advanced Site Solutions ( MASS™ ) in the mobile infrastructure market. Through this equity infusion, we are able to further expand our marketing and sales internationally with our portfolio of state of the art radio products within Advanced Site Solutions says Mats Gustavsson, CEO and co-founder of Microdata. We believe that InnovationsKapital will be a valuable partner as we grow the company. Microdata is led by an impressive team with solid experience both from the industry and from building companies, says Martin Falkevall from InnovationsKapital. We have been impressed by their early customer traction and are looking forward to an exciting journey together with the company in the coming years For further information, please contact: Mats Gustavsson CEO Microdata Telecom Innovation AB +46 708 15 69 25 mats.gustavsson@microdata.se Martin Falkevall InnovationsKapital Nordic Advisor AB +46 8 54 50 14 90 martin.falkevall@innkap.se Linda Höljö InnovationsKapital Nordic Advisor AB +46 8 54 50 14 90 linda.holjo@innkap.se Microdata Telecom Innovation AB offers cost effective radio solutions to OEMs and Network Operators, in order to improve radio coverage, capacity and quality of mobile communications. The company has offices in Täby, Sweden and in India. For further information, please visit: www.microdata.se InnovationsKapital was founded in 1994 as an independent private equity/venture capital firm focused on investments in growth companies. Our investment strategy is to invest in technology companies in the Nordic countries. InnovationsKapital has invested in over 60 companies and Carmen Systems, Formex, Kreatel, Nordnav and Spotfire are some examples of successful exits. InnovationsKapital currently advises four venture funds aggregating over 3 billion SEK (or about 300 million Euro), raised from well renowned Swedish and international institutional investors. For further information about InnovationsKapital, please visit our webpage: www.innkap.se

innkapNews - 8 December, 2009 - InnovationsKapital: Medius is raising external capital to fund international expansion

2009-12-08 09:20:21
Medius, which prior to the equity issuance had been owned by management and personnel, has grown organically and profitably every year since its founding in 2002. The last three years (2006-2008), the company’s revenue has increased by 430% and is on target to reach 90 million SEK (or about 9 million Euro) in 2009. A strategic plan for 2010-2012 includes offering part of the company’s products in non-domestic markets, and in 2012, 40% of revenue is planned to come from markets outside of the company’s home country. Medius is a well established company in Sweden with over 300 customers, including, among others, Saab, Haldex, Stadium, Mekonomen, K-rauta, and The Body Shop. This equity injection gives the company the opportunity to continue its rapid expansion in the rest of the Nordic countries, the Netherlands, Germany, the UK, and in France. Through this equity infusion, we are able to carry out the expansion plans that we have for the upcoming three years. We see an enormous market opportunity for our workflow platform offering, MediusFlow, in markets that we are planning to expand into in the years 2010 through 2012. Given that we in only a matter of a few years have become market leading in Sweden within certain applications – for example support for the purchase to payment process, where support for handling of invoicing has been wildly successful – we are confident that this international expansion will be successful as well, says Per Nordling, CEO and co-founder of Medius. We have been in discussions with a number of venture capital firms, and realized early on that InnovationsKapital was the best partner for Medius at this time. Through their prior investments they have shown good judgment and they take a long term perspective, Per Nordling continues. Medius has all the attributes that we look for in new investments – a great team, a strong and competitive customer offering, and a fast growing market, say Peder Holm and Fredrik Cronqvist from InnovationsKapital. We are looking forward to helping Medius and the existing shareholders in this upcoming expansion. For further information, please contact: Per Nordling CEO Medius AB +46-13-12 16 30 per.nordling@medius.se Peder Holm InnovationsKapital Nordic Advisor AB +46-8-54 50 14 90 peder.holm@innkap.se Fredrik Cronqvist InnovationsKapital Nordic Advisor AB +46-8-54 50 14 90 fredrik.cronqvist@innkap.se Medius aspires to deliver the world‘s best business system support covering all aspects from the requirement setting phase to, and including, the administration phase. This span is dealt with in three business areas: Consulting, ERP, and Workflow. For the Nordic market, Medius works within all three business areas. In the markets outside of the Nordic countries, Medius primarily focuses on the offerings of the Medius workflow business area, i.e. Workflow™. Medius is currently represented in Sweden (headquarters), the Nordic countries, the Netherlands, Germany, the UK, France, United Arab Emirates, and in Poland. Through our global partners we reach organizations all over the world. For further information, please visit: www.medius.se InnovationsKapital was founded in 1994 as an independent private equity/venture capital firm focused on investments in growth companies. Our investment strategy is to invest in technology companies in the Nordic countries. InnovationsKapital has invested in over 60 companies and Carmen Systems, Formex, Kreatel, Nordnav and Spotfire are some examples of successful exits. InnovationsKapital currently advises four venture funds aggregating over 3 billion SEK (or about 300 million Euro), raised from well renowned Swedish and international institutional investors. For further information about InnovationsKapital, please visit our webpage: www.innkap.se

innkapNews - 4 December 2009 - InnovationsKapital: PBM Sweden AB and InnovationsKapital initiate a long-term relation where InnKap 4 Partners LP initially invests SEK 7.5 million.

2009-12-07 15:55:17
Customers are mainly county councils, insurance companies and private companies. ”InnovationsKapital is a serious, long term and stabile investor with a strong track record of helping companies grow and realise their potential”, says the senior consultant Nils Edelstam (M.D.), PBM. PBM is currently based in six cities - Stockholm, Göteborg, Malmö, Gävle, Hudiksvall and Söderhamn. PBM plans to start further business in Sweden and the other Nordic countries. InnovationsKapital invests in young Nordic companies within the Healthcare & Life Sciences and ICT sectors. ”PBM is a very qualified company that continuously delivers excellent and lasting results to its customers. We are convinced that they will grow rapidly in this expansive market”, says Gunnar Fernström being responsible for InnovationsKapital’s investment in PBM. In total InnKap 4 Partners LP will invest up to SEK 19 million in this round of finance. For more information, please contact Tina Nikolaidou, Market Director, PBM, +46 70-569 28 82, www.pbm.se Gunnar Fernström, Investment Director, InnovationsKapital +46 70-312 05 02 gunnar.fernstrom@innkap.se www.innkap.se InnovationsKapital InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, over 65 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 323 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors. Further information about InnovationsKapital can be found at www.innkap.se

innkapNews - 30 June 2009 - InnovationsKapital: Projectplace’s new owners reinforces European strategy

2009-07-06 15:02:14
On Friday June 26, 2009, Projectplace International AB, Europe’s leading online project collaboration tool, was acquired by three venture capital companies. The buyers all have prior relationships with the company and good insight and understanding of its business. The ownership change is a step in the company's continued development and strengthens its future opportunities. - “We are already well established as the market leader in Sweden and Norway and are growing rapidly in Germany and the Benelux region. The new ownership provides us the ability to continue strengthening our position in existing markets while expanding in new European markets”, says Pelle Hjortblad, CEO, Projectplace International. Projectplace International’s business has been growing 30% per year the last three years. The turnover amounted to SEK 129 million in 2008. With the new owners on board the company see a strong opportunity for continued rapid expansion through organic growth as well as strategic acquisitions. - “We have had an eye on Projectplace International for a while”, says Anders Grånäs, Via Venture Partners. “When we got the opportunity to complete this deal, it was a very easy decision for us. The process has been fast and all parties agree.” - “Projectplace International is an innovative, well-run company with high development potential”, says Anders Ösund, Investor Growth Capital. “As an existing owner, we have followed the company for many years. With a clear Europe focused strategy, the company has a great opportunity to increase its growth rate further in coming years.” Investor Growth Capital, Via Venture Partners and InnovationsKapital will each own 30% of the company. The remaining 10% will be offered to a number of key employees within the company - “We are very pleased that the company's management and key employees want to invest and thereby take an active part in the company's continued development. We strongly believe that Projectplace has great potential and are very happy that the management clearly feels the same way”, says Magnus Berglind, InnovationsKapital. Contact: Projectplace International, Pelle Hjortblad, CEO, tel. +46 701810110 Investor Growth Capital, Anders Ösund, tel. +46 73 5241824 Via Venture Partners, Anders Grånäs, tel. +46 734441001 InnovationsKapital, Magnus Berglind, tel. +19175820396 Public Relations Projectplace International: Anna Ålenius Mathson, PR Manager Tel: +47 708 93 02 46, email: anna.alenius.mathson@projectplace.com Since 1998, Projectplace International has developed and provided Europe's leading web tool for project collaboration. The company, with 100 employees, is based in Stockholm, Sweden, with local offices in Denmark, Germany, The Netherlands, and Norway. For more information, please visit www.projectplace.com

innkapNews - 18 April, 2009 - InnovationsKapital: Ignis ASA Acquires Syntune AB

2009-04-20 11:37:18
The acquisition will widen the Ignis product range to include active components, and together with the existing passive components portfolio provide a broader optical offering to network operators. Ignis will issue 8.05 million shares as compensation for 100 % of the shares in Syntune AB to the sellers, which include the leading institutional investors InnovationsKapital and Vision Capital, and founders. Syntune will have a cash position of approximately SEK 25 million prior to the acquisition, and interest bearing debt of approximately SEK 41.8 million. In addition Syntune has established a new loan facility of EUR 2.3 million, Syntune's cash position is considered sufficient to fund its activities until break even during 2010. The company completed the qualification of its first generation of products in 2007. Ramp-up of revenue began at the end of 2007, and amounted to gross SEK 18 million in products sold in 2008, with a significant growth speed into 2009. With Syntune as a 100 % owned subsidiary, Ignis will strengthen its technology platform in a crucial area, tunable laser technology, and in addition get some of the best expertise in the optical industry. Tunability is becoming one of the most critical elements of the optical industry, as wavelength agility offers cost reductions and increased flexibility for optical network operators. Ignis ASA signed a Letter of Intent to acquire Syntune AB earlier in April. After the approval by the Board of Directors in Ignis, the acquisition remains contingent on approval by the General Meeting in Ignis ASA. By acquiring Syntune, Ignis maintains its strategy in taking an active part in the ongoing global industry consolidation. A detailed stock exchange notification about the transaction will follow on Monday the 20th of April. On the same day the company management will present further details about the acquisition at 10 am, at the Felix Conference Centre, Aker Brygge. The presentation will be published via webcast. See Ignis homepage. About Ignis ASA Ignis ASA comprises the business division Ignis Technology, which includes 69.3% ownership in Fi-ra Photonics in Korea and the wholly owned subsidiary Ignis Photonyx - with operations in Denmark, Norway and Canada. Fi-ra is first and foremost provider of optical splitters to large system houses and telecom operators in South-East Asia,while Ignis Photonyx over the last years has been focusing on investing in the development of AWG`s for the next generation high-capacity broadband network WDM-PON. About Syntune AB Syntune AB (www.syntune.com) supplies state-of-the-art widely tunable lasers for applications ranging from fiber-optic communications to sensor systems. In communications, Syntune's lasers enable universal DWDM transceivers with low power consumption in a small form factor. These drastically reduced overhead costs for sparing and maintaining inventories. Tunability also enables flexible networks, which allows operators to offer innovative services and reduces their operational expenditures. About InnovationsKapital InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable us to invest in successful early stage and growth companies. We support talented entrepreneurs to help them create successful high growth businesses. Since 1994, we have made over 58 investments and a number of successful exits in the life sciences and technology sectors. For further information, please contact: Thomas Ramm, CEO, Ignis ASA Tel: +47 913 70 795

innkapNews - June 18, 2008 - InnovationsKapital: CapMan and InnovationsKapital invest in Crayon

2008-07-27 00:00:00
Crayon advises its clients in software procurement processes and simplifies the clients' software license administration. In addition Crayon offers consulting and training around the purchased software to its clients, which include a number of large Nordic customers within both private and public sectors. The company was founded in 2002 and it has headquarters in Oslo and offices in Trondheim, Stockholm, Umeå, Copenhagen and Helsinki. Crayon's net sales totalled some MEUR 48 in 2007 and the company employs some 190 people. “The company has a truly unique offering in software asset management, combining the work normally done by a value added reseller with skilled management consulting, which has resulted in a strong growth in sales and very satisfied customers”, says CapMan's Investment Director Julia Reuszner. “Crayon has a very strong market position both in Norway and Sweden and we believe there is potential to develop this further and address new geographies and a wider customer base”, says InnovationsKapital's Investment Director Martin Falkevall. “For us the investment made by CapMan and InnovationsKapital is a great acknowledgement of what Crayon has achieved over the last years .We believe that the investment can help us to the next level in our growth ambition”, says Crayon's Chairman of the Board Jens Rugseth. CapMan Technology 2007 fund and InnovationsKapital will own 20% of Crayon's parent company Artix's shares with equal holdings after the transaction has been completed. The current owners, including management and employees, will hold the reminder of the shares. The closing of the transaction is subject to certain conditions agreed with the parties in the transaction to be met. CapMan Plc is a substantial investor in CapMan Technology 2007 fund. For more information, please contact: Julia Reuszner, Investment Director, CapMan Technology tel. +46 8 545 854 70 or +46 739 865 664 Martin Falkevall, Investment Director, InnovationsKapital tel. +46 8 54 50 14 90 or +46 708 47 73 16 Jens Rugseth, Chairman of the Board, Crayon tel. +47 22 89 10 00 or +47 91 16 94 40 CapMan www.capman.com CapMan is one of the leading alternative asset managers in the Nordic countries and manages Nordic funds with approximately EUR 3.1 billion in total capital. CapMan has five investment areas (CapMan Buyout, CapMan Technology, CapMan Life Science, CapMan Russia and CapMan Real Estate), and each of them has a dedicated team and funds. Altogether CapMan employs 130 people in Helsinki, Stockholm, Copenhagen, Oslo and Moscow. CapMan was established in 1989 and its B shares are listed on the Helsinki Stock Exchange since 2001. InnovationsKapital www.innkap.se InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable us to invest in successful early stage and growth companies. We support talented entrepreneurs to help them create successful high growth businesses. Since 1994, we have made over 58 investments and a number of successful exits in the life sciences and technology sectors. Crayon www.crayon.no Crayon is a successful provider of software asset management and licenses, consulting services and training courses. Established in 2002, Crayon has operations in Norway, Sweden, Finland and Denmark and employs 190 people.

innkapNews - July 8, 2008 - Xtract: Xtract, Innovator in Social Advertising Intelligence Raises EUR 7.5 Million

2008-07-08 00:00:00
London, UK and Helsinki, Finland – July 8, 2008: Xtract, the leader and innovator in social advertising intelligence today announced that it has closed its series B round of funding with EUR 7,5 Million ($11.74M) from leading early-stage technology investors Creandum, ETF III advised by Eqvitec Partners and InnovationsKapital. Xtract enables mobile and online companies to refine their customer data creating highly accurate 3 Dimensional profiles combining social interactions, behaviour and demographic information. It answers a crucial need in the advertising industry by making the advertising in social media and mobile effective. By using Xtract, customers have seen the average ad income increase with as much as 82% and in mobile campaigns response rates have increased, on an average, with 30%. Staffan Ingeborn, Managing Investment Director of InnovationsKapital comments: “Xtract is a very exciting company with a unique proposition for targeting of digital advertising. Its solutions have been shown to create substantial value for its customers, and we believe that Xtract is very well positioned to become a winner and a leader in this space.” Xtract works with over 50 companies with intensive customer data ranging from global leaders such as Nokia, T-Mobile and Vodafone to innovative challengers such as BLYK and Flirtomatic. Xtract makes complexity simple and actionable via a unique and patented set of products that based upon social interactions, behaviour data and other dataflow can create accurate and dynamic real-time customer profiles. Xtract can ensure delivery of the right audience to the right commercial message at the right time and accurately report on the effectiveness of any campaign. Something which up until now was not possible. Xtract board member Juha Mikkola of Eqvitec Partners said: “This investment opportunity had a lot of demand and clearly marks the very interesting market and expansion opportunity that Xtract represents in the fast growing social intelligence market.” “We are delighted to have added two new prominent investors, InnovationsKapital and Creandum in addition to our original investor ETF III advised by Eqvitec Partners. This investment round combined with an exceptional organic growth enables us to expand to new markets outside Europe,” says Kimmo Kiviluoto, CEO of Xtract. About Creandum Creandum is a Nordic venture capital firm investing in early-stage technology companies. The firm has 120 million Euros under management and is today the fastest growing independent partnership of its kind in the Nordic region. Creandum invests in innovative companies in high growth markets led by outstanding entrepreneurs. All investment professionals at Creandum have started companies or been part of successful startups. For more information, please visit www.creandum.com About Eqvitec Partners Oy Eqvitec Partners Oy is one of the largest technology focused venture capital and private equity firms in Northern Europe. The company was founded in 1997 and employs 15 investments professionals in Helsinki and Stockholm. Eqvitec Partners currently advises 6 funds with the total capital base of 500 million Euros. The funds invest in technology companies in all phases from start-up to buyouts. At the moment the funds have investments in 40 companies and have carried out 35 exits. More information can be found at www.eqvitec.com About InnovationsKapital InnovationsKapital is a leading independent venture capital firm in the Nordic region with capital commitments of EUR 317 million in four funds. Years of experience and a strong network within academia and industry enable InnovationsKapital to invest in successful early stage and growth companies. InnovationsKapital supports talented entrepreneurs to help them create successful high growth businesses. Since 1994, InnovationsKapital has made over 60 investments and a number of successful exits in the life sciences and technology sectors. For more information, please visit www.innkap.se About Xtract Xtract is the global trusted partner and innovator in Social Advertising Intelligence. We have the technology and competence to turn large user data into cash flow. Our solutions create accurate and automated consumer profiles for mobile and online advertisers based on social interactions, behavioural and demographic data. Xtract operates across Europe and Asia, working with over 50 companies with intensive customer data ranging from global leaders such as Nokia, T-Mobile and Vodafone to innovative challengers such as BLYK and Fonecta. Headquarters are in Helsinki, Finland and London, UK. www.xtract.com

innkapNews - June 27, 2008 - InnovationsKapital: Isconova secures 30 million Swedish kronor growth financing

2008-06-27 00:00:00
Leading vaccine adjuvant provider set to grow in animal vaccine market and to unlock the value of its technology for human vaccines. Uppsala, 27 June 2008. Isconova AB, announced today that it has secured financing of 30 million Swedish kronor ( 3,3 m€ ) from InnovationsKapital, a leading Nordic venture capital firm, and a group of private investors. Isconova is a pioneer in vaccine adjuvant technology, with a proprietary, safe and effective ISCOM technology. ”We are extremely pleased to have attracted the support of InnovationsKapital, who have a successful record of backing innovative growth biotech companies in Scandinavia. This new investment will allow Isconova to increase our production capacity and to invest in marketing,” said Bengt Falk, Isconova's CEO. “It will enable us to build on our existing growth in the animal vaccine sector. We will also be able to accelerate our activities in human vaccines where we already have a very promising partnership on an influenza vaccine.” Isconova's scientific excellence in the vaccine adjuvant field is backed by commercial validation through several agreements with major healthcare partners and on-market veterinary vaccines. “We feel excited about Isconova's future,” commented Johan Rask and Ulf Tossman at InnovationsKapital. Isconova's adjuvant makes vaccines more protective and longer-lasting. This fills a critical need for safe and effective adjuvants in the fast-growing vaccine industry. Isconova has established a significant production capacity in Uppsala and is already supplying its Matrix adjuvant to corporate partners for use in animal vaccines. For further information please contact: At Isconova: Bengt Falk, CEO, Isconova phone +46 703 022254 email bengt.falk@isconova.se At InnovationsKapital: Ulf Tossman, Investment Director, InnovationsKapital phone +46 705 630858 email ulf.tossman@innkap.se Johan Rask, Investment Manager, InnovationsKapital phone +46 708 946060 email johan.rask@innkap.se About Isconova AB, www.isconova.se Isconova, based in Uppsala, Sweden was established in 2000 by scientists from the Swedish Agricultural University. The Company's mission is to use its safe and effective ISCOM technology platform to deliver innovative vaccines. ISCOM is already established as the dominant vaccine adjuvant for horse vaccines in Europe. Isconova has licensed its technology to major vaccine corporations, including Intervet, Schering Plough, Pfizer and Crucell. Isconova will continue to drive growth by extending the use of its adjuvant into dogs, cats and livestock. New developments will allow Isconova to develop research projects to explore the use of ISCOM in human vaccines. About InnovationsKapital, www.innkap.se InnovationsKapital was founded in 1994 and is a private and independent early stage venture capital firm for innovative growth companies. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. To date, more than 60 investments have been made. Successful exits include Altitun, Arexis, BioInvent/Alligator, Carmen Systems, Kreatel Communications, NordNav and Spotfire. InnovationsKapital advises four venture capital funds aggregating EUR 317 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors.

innkapNews - June 11, 2008 - Syntensia: Syntensia Secures Expansion Financing - Leading Network Security-on-Demand Company Charts Further Growth in Emerging Markets

2008-06-11 00:00:00
NEW YORK, June 3, 2008 - Syntensia AB, a pioneer in subscription Network Security-On-Demand solutions, has secured financing of $3.5 million with an option for an additional $4 million through a share issue directed to InnovationsKapital, a leading Nordic venture capital firm, and a group of private investors in Sweden and abroad. Syntensia chairman is John Wattin. Syntensia, headquartered in Stockholm and with sales offices in twenty major Indian cities, Philippines and Cambodia was established in 2005 by Kaushik Thakkar. It focuses on providing all-in-one network security solutions for SMB in high growth emerging markets. "This investment allows Syntensia to continue our solid growth in India and our expansion in Cambodia and the Philippines," said Syntensia CEO Johan Hansson. "It also makes possible expansion into other Asian markets. We are particularly pleased to have attracted the support of InnovationsKapital, which has a reputation for backing innovative growth companies in Scandinavia." “Syntensia is capitalizing on the powerful combination of a low cost, high demand product offering to fast growing markets. We are very pleased with our investment in Syntensia and feel very excited about the company's potential,” said InnovationsKapital's Investment Director Magnus Berglind. Syntensia's WK product series is the most cost-effective and comprehensive network security solution for SMB available in the market today. These hardware-based appliances are Plug and Play ready, all-in-one network security solutions that integrate seven crucial security check points - Firewall, VPN, Intrusion Protection, Anti Virus, Spam Elimination, Surf Protection and Spyware Guarding and are available for a nominal subscription fee. Syntensia’s subscription model typically bundles everything into its single subscription fee, including automatic updates, maintenance and 24X7 technical support, thus enabling organizations to eliminate upfront costs, providing a predictable cost structure, and ensuring quality of service and the freedom to re-evaluate the solution decision any time. For further information please contact: Johan Hansson, CEO, Syntensia Phone: +1 917 582 0753 Email: johan@syntensia.com Magnus Berglind, Investment Director, InnovationsKapital Phone: +1 917 582 0396 Email: magnus.berglind@innkap.com InnovationsKapital InnovationsKapital (www.innkap.com) was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors. Syntensia AB Syntensia AB (www.syntensia.com) is a European Company headquartered in Stockholm, Sweden. Established in 2005, Syntensia is a pioneer in Security on-demand solutions sold on subscription basis. Syntensia focuses on providing all-in-one network security solutions for SMB in high growth emerging markets.

innkapNews - Sept 24, 2007 - InnovationsKapital: Apptus expands with help of InnovationsKapital

2007-09-24 00:00:00
Apptus Technologies AB - a Swedish challenger in the global market for search technology in the e-directory and e-commerce sector - announced today that InnovationsKapital, the leading Nordic private equity/venture capital fund has become a new investor in the company. Since its founding in 2000, Apptus Technologies has positioned itself as the leader in the e-directory and e-commerce sector in the Nordic countries. As a result, Apptus' technology platform is currently used by top tier customers such as, Eniro, Hitta and CDON.COM. In collaboration with InnovationsKapital, Apptus will increase its efforts on international expansion, continue the strong focus on sales and broaden the Apptus product portfolio. "With InnovationsKapital in our corner, we can scale up operations and take aggressive measures to become a leading international player in search technology. We have recently won our first customers in England and Canada, and we see this as a springboard out into the world," says Apptus CEO Michael Atlevi. "Apptus is a very exciting company with a unique offering to its customers, as well as strong and proven products and an impressive Nordic customer base. We are looking forward work with the Apptus team to build on their already widely successful Nordic presence. We strongly believe Apptus has the potential to become a dominating player in the global marketplace," says Martin Falkevall, Investment Director at InnovationsKapital. "Apptus position in the Nordic market has improved dramatically during 2007. We continue building our world class team, expand our product line and increase sales by 70 percent this year. InnovationsKapital will take an active role on our board of directors, bringing a strong track record and extensive experience in international expansion. We are launching several major initiatives for which we are well-equipped, thanks to our stable foundation, both when it comes finances and expertise," says Gertrud Elisabet Bohlin, Chairperson of the Board, Apptus Technologies AB. For more information, please contact: Gertrud Elisabet Bohlin, Chairwoman of the Board, Apptus Technologies AB Phone: +46 705-669526 E-mail: geb@queenab.se Martin Falkevall, Investment Director, InnovationsKapital Phone: +46 708- 47 73 16 E-mail: martin.falkevall@innkap.se More about Apptus Apptus Technologies AB is leading in search and database technology in the Nordic countries. The company provides solutions and products that assure availability for customers with growing data volumes and stringent demands on search logic, relevant results and connections to customers' operations. Apptus primarily supplies solutions to customers in the e-directory and e-commerce sector. Among the Nordic customers are Bokus, CDON.COM, De Gule Sider, Eniro, Hitta.se, Lunarstorm, Sveriges Radio, Torget Sverige, etc. Apptus conducts research in search and database technology. Apptus stands for quality, results and growth. For more information, please visit http://www.apptus.com. More about InnovationsKapital InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT, Healthcare & Life Sciences and Clean Tech - dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnovationsKapital currently advises four venture funds aggregating EUR 320 million in committed capital. The capital is provided by international institutional investors. For further information, please visit http://www.innkap.se